NZ762916A - Improving material identification using multi-energy ct image data - Google Patents
Improving material identification using multi-energy ct image data Download PDFInfo
- Publication number
- NZ762916A NZ762916A NZ762916A NZ76291616A NZ762916A NZ 762916 A NZ762916 A NZ 762916A NZ 762916 A NZ762916 A NZ 762916A NZ 76291616 A NZ76291616 A NZ 76291616A NZ 762916 A NZ762916 A NZ 762916A
- Authority
- NZ
- New Zealand
- Prior art keywords
- voxels
- energy
- image data
- reconstructed
- data set
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 447
- 238000000034 method Methods 0.000 claims abstract description 322
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 181
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 139
- 238000002591 computed tomography Methods 0.000 claims abstract description 130
- 238000003384 imaging method Methods 0.000 claims abstract description 44
- 238000013500 data storage Methods 0.000 claims abstract description 27
- 238000012545 processing Methods 0.000 claims abstract description 21
- 238000004590 computer program Methods 0.000 claims abstract description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 62
- 210000004872 soft tissue Anatomy 0.000 claims description 49
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 229910052751 metal Inorganic materials 0.000 claims description 22
- 239000002184 metal Substances 0.000 claims description 22
- 239000007943 implant Substances 0.000 claims description 19
- 238000009826 distribution Methods 0.000 claims description 17
- 150000002739 metals Chemical class 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012925 reference material Substances 0.000 claims description 5
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 description 91
- 210000001519 tissue Anatomy 0.000 description 82
- 241001465754 Metazoa Species 0.000 description 53
- 150000002632 lipids Chemical class 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 229910001868 water Inorganic materials 0.000 description 42
- 210000000845 cartilage Anatomy 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 33
- 230000011218 segmentation Effects 0.000 description 30
- 239000003814 drug Substances 0.000 description 29
- 239000002105 nanoparticle Substances 0.000 description 27
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 26
- 229910052740 iodine Inorganic materials 0.000 description 26
- 239000011630 iodine Substances 0.000 description 26
- 238000011002 quantification Methods 0.000 description 25
- 239000011159 matrix material Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 229910052688 Gadolinium Inorganic materials 0.000 description 18
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 18
- 239000010931 gold Substances 0.000 description 18
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 16
- 239000002872 contrast media Substances 0.000 description 16
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 15
- 229910052737 gold Inorganic materials 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 230000008901 benefit Effects 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000012377 drug delivery Methods 0.000 description 13
- 238000012544 monitoring process Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000036541 health Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 11
- 230000003595 spectral effect Effects 0.000 description 11
- 208000004434 Calcinosis Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 206010003210 Arteriosclerosis Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 235000013372 meat Nutrition 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 9
- 239000004926 polymethyl methacrylate Substances 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- 238000013170 computed tomography imaging Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000002308 calcification Effects 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 238000000326 densiometry Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 235000019687 Lamb Nutrition 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 229910052715 tantalum Inorganic materials 0.000 description 6
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 6
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 6
- 229910052721 tungsten Inorganic materials 0.000 description 6
- 239000010937 tungsten Substances 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 229910052769 Ytterbium Inorganic materials 0.000 description 5
- 229910052797 bismuth Inorganic materials 0.000 description 5
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 229910052735 hafnium Inorganic materials 0.000 description 5
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 229910052701 rubidium Inorganic materials 0.000 description 5
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 5
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 5
- 229910052727 yttrium Inorganic materials 0.000 description 5
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 5
- 241000282994 Cervidae Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- HUHDYASLFWQVOL-WZTVWXICSA-N 3-[[2-[[3-[acetyl(methyl)amino]-2,4,6-triiodo-5-(methylcarbamoyl)benzoyl]amino]acetyl]amino]-5-(2-hydroxyethylcarbamoyl)-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I HUHDYASLFWQVOL-WZTVWXICSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000007660 Residual Neoplasm Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 230000037180 bone health Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000030270 breast disease Diseases 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 208000037408 Device failure Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000002073 nanorod Substances 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003349 osteoarthritic effect Effects 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 210000005065 subchondral bone plate Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010048782 Breast calcifications Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229910010038 TiAl Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002083 X-ray spectrum Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- -1 adipose tissue Chemical class 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037186 bone physiology Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- OCDAWJYGVOLXGZ-VPVMAENOSA-K gadobenate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)C(C([O-])=O)COCC1=CC=CC=C1 OCDAWJYGVOLXGZ-VPVMAENOSA-K 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(III) nitrate Inorganic materials [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Apparatus For Radiation Diagnosis (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Abstract
Described is a computer-implemented method for selecting a material decomposition algorithm using image data generated using a multi-energy computer tomography (CT) imaging system using three or more energy bands using a computer program product, the method including receiving a reconstructed or non-reconstructed multi-energy CT image data set produced using three or more energy bands in relation to an object, storing said data set on a data storage medium, processing the data using one or more reconstruction techniques to produce a data set of reconstructed voxels, comparing each voxel in the reconstructed data set to a reference set of material signal amplitude and noise properties stored on a data storage medium, classifying the voxels into air, low density or high density voxels, selecting a first material decomposition method to be applied to low density voxels and/or selecting a second material decomposition method to be applied to higher density voxels; and presenting the selected first and/or second decomposition method to an interface. ALso described are systems for carrying out the computer implemented method.
Description
Improving Material Identification using Multi-Energy CT Image Data
Field of Invention
This invention relates to the use of multi-energy computed tomography (CT) to identify and
to quantify different materials within an object. More specifically, methods for processing
multi-energy CT images are discussed, with reference to different applications.
Background to the Invention
Multi-energy computed tomography (CT) is an x-ray imaging modality which produces 3D
images of the inside of objects. CT scanners use polychromatic x-ray sources which emit a
full rainbow of x-rays with various colours (x-ray energies). In regular CT there is no
distinction made between the different energies of x-rays. However x-rays are absorbed
differently by different materials in the body, and differently again for x-rays of different
energies. Multi-energy CT measures the absorption of x-rays in different energy ranges.
Using the differences in x-ray absorption in these energy ranges it is possible to discriminate
between (identify) and quantify various materials in an object.
A major role of material analysis algorithms in multi-energy CT is to assign to each voxel in
the reconstructed CT image the quantity of one or more materials from a dictionary of
possible materials which may be present. This poses a significant problem as many of the
materials that one would include in this dictionary have very similar x-ray attenuation
properties. When the dictionary has a large number of similar materials then the inversion
techniques used for material analysis algorithms are numerically unstable - producing
nonsensical results.
Another common problem faced by all material detection and quantification algorithms is
the incorrect identification of one material as another. There are three types of material
misidentification which are typically encountered. The first type results from numerical
instability when decomposing into a basis containing a large number of materials. Large
material basis sets are ill-conditioned due to the similarities in attenuation between
different materials. The second type results from omitting materials from the
decomposition to achieve a more stable inversion. This however will project non-
represented materials onto the given basis, describing them as a combination of different
materials. The third type occurs when material decomposition is done on poor quality data
with significant image artefacts such as excessive noise.
The problems above have made it difficult to identify and quantify large numbers of
different materials within a multi-energy CT scan. Known material decomposition methods
have achieved the discrimination of four different materials (excluding air) or five (including
air) using multi-energy CT. However, it would be advantageous to establish a method that is
able to discriminate and identify larger numbers of different materials using a multi-energy
CT scanning system.
Object of the Invention
It is an object of the invention to provide a method or methods for more effective
quantification of different materials within an object using image data generated from a
multi-energy CT imaging apparatus.
Alternatively, it is an object to provide new methods for post reconstruction material
decomposition of multi-energy spectral CT data.
Alternatively, it is an object of the invention to provide an improved method, system and
computer program for selection and presentation of a material decomposition algorithm to
be used on image data generated using a multi-energy computer tomography (CT) system.
Alternatively, it is an object of the invention to provide an improved method, system and
computer program product for improved quantification of different materials within an
object.
Alternatively, it is an object of the invention to at least provide the public with a useful
choice.
Alternatively, it is an object of the invention to provide a method and system to identify and
quantify various different materials intrinsic to humans and animals.
Summary of the Invention
According to a first embodiment of the invention there is provided a method for selecting a
material decomposition algorithm using image data generated using a multi-energy
computer tomography (CT) system, the method including;
a) scanning an object using a multi-energy CT system to produce a set image data;
b) applying one or more reconstruction techniques to the set image data to
produce a set of reconstructed voxels;
c) comparing each voxel to a reference set of material signal amplitude and noise
properties in order to classify the voxels into air, low density or high density
voxels; and
d) based on the determination of c) selecting a first material decomposition method
to be applied to low density voxels and/or selecting a second material
decomposition method to be applied to higher density voxels.
According to a second embodiment of the invention there is provided a computer-
implemented method for selecting and presenting a material decomposition algorithm
using image data generated using a multi-energy computer tomography (CT) imaging system
using a computer program product, the method including;
a) scanning an object using a multi-energy CT system to produce a set of image
data;
b) sending the set of image data to a processor;
c) receiving the set image data set in relation to an object;
d) storing said data on a data storage medium;
e) processing the data using one or more reconstruction techniques to produce a
data set of reconstructed voxels;
f) comparing each voxel in the reconstructed data set to a reference set of material
signal amplitude and noise properties stored on a data storage medium;
g) classifying the voxels into air, low density or high density voxels;
h) based on the determination of g) selecting a first material decomposition
method to be applied to low density voxels and/or selecting a second material
decomposition method to be applied to higher density voxels; and
i) presenting the selected first and/or second decomposition method to an
interface.
Preferably, the step of classifying voxels as air, low density or high density voxels includes
comparing individual voxels to a reference distribution of a specific reference material using
the Mahalanobis distance metric and Euclidian distance metric.
More preferably, the step of classifying voxels further includes the step of filtering the data
to remove noise.
According to a third embodiment of the invention, there is provided a system for selecting
and presenting a material decomposition algorithm using image data generated using a
multi-energy computer tomography (CT) imaging system, the system comprising:
a) a means for scanning an object using a multi-energy CT system to produce a set
of image data;
b) a means for sending the set of image data to a processor;
c) a means for receiving the set of multi-energy CT image data set in relation to an
object;
d) a means for storing said data on a data storage medium;
e) a means for processing the data using one or more reconstruction techniques to
produce a data set of reconstructed voxels;
f) a means for comparing each voxel in the reconstructed data set to a reference
set of material signal amplitude and noise properties stored on a data storage
medium;
g) a means for classifying the voxels into air, low density or high density voxels;
h) a means for, based on the determination of g), selecting a first material
decomposition method to be applied to low density voxels and/or selecting a
second material decomposition method to be applied to higher density voxels;
i) a means for presenting the selected first and/or second decomposition method
to an interface.
According to a fourth embodiment of the invention there is provided a method for selecting
a material decomposition algorithm using image data generated using a multi-energy
computed tomography (CT) imaging system, the method including;
a) receiving reconstructed or non-reconstructed multi-energy CT image data in
relation to an object;
b) if non-reconstructed, applying one or more reconstruction techniques to the set
of images to produce a set of reconstructed voxels;
c) comparing the each voxel to a reference set of material signal amplitude and
noise properties in order to classify the voxels into air, low density or high
density voxels; and
d) based on the determination of c) selecting a first material decomposition method
to be applied to low density voxels and/or selecting a second material
decomposition method to be applied to higher density voxels.
According to a fifth embodiment of the invention there is provided a computer-
implemented method for selecting a material decomposition algorithm using image data
generated using a multi-energy computer tomography (CT) imaging system using a
computer program product, the method including;
a) receiving a reconstructed or non-reconstructed multi-energy CT image data set in
relation to an object;
b) storing said data on a data storage medium;
c) if data received in a) is non-reconstructed, processing the data using one or more
reconstruction techniques to produce a data set of reconstructed voxels;
d) comparing each voxel in the reconstructed data set to a reference set of material
signal amplitude and noise properties stored on a data storage medium;
e) classifying the voxels into air, low density or high density voxels;
f) based on the determination of e) selecting a first material decomposition
method to be applied to low density voxels and/or selecting a second material
decomposition method to be applied to higher density voxels; and
g) presenting the selected first and/or second decomposition method to an
interface.
Preferably, the method further includes the step of scanning an object using a multi-energy
CT system to produce a set of image data and the step of sending image data.
More preferably, the step of classifying voxels as air, low density or high density voxels
includes comparing individual voxels to a reference distribution of a specific reference
material using the Mahalanobis distance metric and Euclidian distance metric.
More preferably, the step of classifying voxels further includes the step of filtering the data
to remove noise.
According to a sixth embodiment of the invention, there is provided a system for selecting
and presenting a material decomposition algorithm using image data generated using a
multi-energy computer tomography (CT) imaging system, the system comprising:
a) a means for receiving a reconstructed or non-reconstructed multi-energy CT
image data set in relation to an object;
b) a means for storing said data;
c) a means for processing the data using one or more reconstruction techniques to
produce a data set of reconstructed voxels;
d) a means for comparing each voxel in the reconstructed data set to a reference
set of material signal amplitude and noise properties stored on a data storage
medium;
e) a means for classifying the voxels into air, low density or high density voxels;
f) a means for selecting a first material decomposition method to be applied to low
density voxels and/or selecting a second material decomposition method to be
applied to higher density voxels; and
g) a means for presenting the selected first and/or second decomposition method
to an interface.
Preferably, the system includes a means for scanning an object using a multi-energy CT
system to produce a set of image data and a means for sending image data.
According to a seventh embodiment of the invention there is provided a method for
material quantification of data produced by a multi-energy CT system to identify and/or
quantify one or more materials represented by the data, the material quantification method
including the steps of:
a) for each of a plurality of reconstructed voxels contained within the data,
enforcing a sparse solution for a maximum number of material combinations
using 0-norm minimisation;
b) applying rejection criteria to the solution of a) to identify one or more specific
materials.
According to an eighth embodiment of the invention, there is provided a computer-
implemented method for identifying and/or quantifying, and presenting one or more
materials represented by data produced by a multi-energy CT system using a computer
program product, the method comprising:
a) receiving, directly or indirectly, an image data set from a multi-energy CT imaging
apparatus and storing said data on a data storage medium;
b) calculating, for each of a plurality of voxels contained within the data set, a sparse
solution for a maximum number of material combinations using 0-norm
minimisation using a processor;
c) storing said sparse solutions on a data storage medium;
d) applying rejection criteria to the sparse solutions of b) to identify one or more
materials; and
e) presenting the materials identified in d) via an interface.
Preferably, the step of calculating the sparse solutions further includes the steps of;
i) determining all combinations of the maximum number of materials present in
the CT image data set;
ii) for each combination, constructing a reduced material matrix M ;
iii) calculating a non-negative linear least squares solution x for the sub problem
M x = one voxel;
iv) determining which solution from iii) has the smallest least square error out of all
the tested combinations determined in i);
v) selecting the solution determined in iv) as the best sparse solution.
Preferably the step of applying rejection criteria to the sparse solutions further includes the
steps of;
i) identifying combinations of materials pre-determined not to be found in the
same voxel and rejecting said combinations; and/or
ii) setting acceptable solution ranges for each material, and rejecting any sub-
problem with a solution outside these ranges.
Preferably, the method includes decomposing data from five or more different materials.
Preferably, the multi-energy CT imaging apparatus used in the method uses two or more
energy bands.
More preferably, the multi-energy CT imaging apparatus uses between two – eight energy
bands.
More preferably, the method includes decomposing data from six different materials using
four energy bands.
In preferred embodiments, the method includes the step of de-noising the data/images for
each energy range prior to decomposition.
More preferably, the step of de-noising includes applying a cylindrical median filter for
reducing high frequency noise.
In preferred embodiments the method includes the further step of enforcing one or more
constraints to the individual material combinations.
According to a ninth embodiment of the invention, there is provided a system for identifying
and/or quantifying one or more materials represented by data produced by a multi-energy
CT system, the system comprising:
a) a means for directly or indirectly receiving an image data set from a multi-energy CT
imaging apparatus;
b) a means for storing said data;
c) a means for calculating, for each of a reconstructed voxel contained within the
image data set, a sparse solution for a maximum number of material combinations
using 0-norm minimisation;
d) a means for storing said sparse solutions;
e) a means for applying rejection criteria to the sparse solutions of c) to identify one or
more specific materials; and
f) a means for presenting the materials identified in d).
According to a tenth embodiment of the invention there is provided a method for
identifying and/or quantifying one or more materials in an object using images produced by
a multi-energy CT system, the method including the steps of;
a) scanning an object using a multi-energy CT system to produce an image data set;
b) applying one or more reconstruction techniques to the image data set to
produce a set of spatially-reconstructed voxels;
c) comparing the density of each voxel to a reference set of material densities in
order to classify the voxels into air, low radiographic density or high radiographic
density voxels;
d) based on the determination of c) selecting a first material decomposition method
to be applied to low density voxels and/or selecting a second material
decomposition method to be applied to higher density voxels; and
e) applying a first material decomposition method to the low density voxels, the
first material decomposition method including using volume constrained non-
negative linear least squares to aid material identification; and/or
f) applying a second material decomposition method to the high density voxels, the
second material decomposition method including using a method that aids
material identification by enforcing a sparse representation of the material
composition for each voxel.
Preferably, the step of applying a second material decomposition method further includes
one or more of the steps as outlined in the seventh embodiment of the invention and the
subsequent preferred embodiments.
According to an eleventh embodiment of the invention there is provided a computer
implemented method for identifying and/or quantifying one or more materials in an object
using images produced by a multi-energy CT system using a computer program product, the
method including the steps of:
a) scanning an object using a multi-energy CT system to produce an image data set;
b) sending the image data set to a processor;
c) receiving the image data set in relation to an object;
d) storing said data on a data storage medium;
e) processing the data using one or more reconstruction techniques to produce a
data set of reconstructed voxels;
f) comparing the radiographic density of each voxel to a reference set of material
radiographic densities in order to classify the voxels into air, low density or high
density voxels;
g) based on the determination of f), selecting a first material decomposition
method to be applied to low density voxels and/or selecting a second material
decomposition method to be applied to higher density voxels;
h) applying a first material decomposition method to the low density voxels, the
first material decomposition method including using volume constrained non-
negative linear least squares to aid material identification; and/or
i) applying a second material decomposition method to the high density voxels, the
second material decomposition method including using an method that aids
material identification by enforcing a sparse representation of the material
composition for each voxel;
j) identifying specific materials with the object based on the solutions from h) and
i); and
k) presenting material identification information on an interface.
Preferably, the step of classifying voxels as air, low density or high density voxels includes
comparing individual voxels to a reference distribution of a specific reference material using
the Mahalanobis distance metric and Euclidian distance metric.
More preferably, the step of classifying voxels further includes the step of filtering the data
to remove noise.
Preferably, the step of applying a second material decomposition method further includes
one or more of the steps as outlined in the eighth embodiment of the invention and the
subsequent preferred embodiments.
According to a twelfth embodiment of the invention there is provided a system for
identifying and/or quantifying one or more materials represented by data produced by a
multi-energy CT system, the system comprising:
a) a means for scanning an object using a multi-energy CT system to produce an
image data set;
b) a means for sending the image data set to a processor;
c) a means for receiving the image data set in relation to an object;
d) a means for storing said data on a data storage medium;
e) a means for processing the data using one or more reconstruction techniques to
produce a data set of reconstructed voxels;
f) a means for applying one or more reconstruction techniques to the set of
projection images to produce a set of reconstructed voxels;
g) a means for comparing the radiographic density of each voxel to a reference set
of material radiographic densities in order to classify the voxels into air, low
density or high density voxels;
h) a means for selecting a first material decomposition method to be applied to low
density voxels and/or selecting a second material decomposition method to be
applied to higher density voxels;
i) a means for applying a first material decomposition method to the low density
voxels, the first material decomposition method including using volume
constrained non-negative linear least squares to aid material identification;
and/or
j) a means for applying a second material decomposition method to the high
density voxels, the second material decomposition method including using an
method that aids material identification by enforcing a sparse representation of
the material composition for each voxel;
k) a means for identifying specific materials within the object based on the
solutions from i) and j); and
l) a means for presenting material identification information on an interface.
According to a thirteenth embodiment of the invention there is provided a method for
identifying and/or quantifying one or more materials using images produced by a multi-
energy CT system, the method including the steps of:
a) receiving a number of reconstructed or non-reconstructed multi-energy CT
image data sets in relation to an object;
b) if non-reconstructed, applying one or more reconstruction techniques to the
image data set to produce a set of reconstructed voxels;
c) comparing each voxel in the reconstructed data set to a reference set of material
signal amplitude and noise properties and classifying the voxels into air, low
density or high density voxels;
d) based on the determination of c) selecting a first material decomposition method
to be applied to low density voxels and/or selecting a second material
decomposition method to be applied to higher density voxels; and
e) applying a first material decomposition method to the low density voxels, the
first material decomposition method including using volume constrained non-
negative linear least squares to aid material identification; and/or
f) applying a second material decomposition method to the high density voxels, the
second material decomposition method including using an method that aids
material identification by enforcing a sparse representation of the material
composition for each voxel.
According to a fourteenth embodiment of the invention there is provided a computer
implemented method for identifying and/or quantifying a number of materials in an object
using image data produced by a multi-energy CT system using a computer program product,
the method including the steps of:
a) receiving a reconstructed or non-reconstructed multi-energy CT image data set in
relation to an object;
b) storing said data on a data storage medium;
c) if data received in a) is non-reconstructed, processing the data using one or more
reconstruction techniques to produce a data set of reconstructed voxels;
d) comparing each voxel in the reconstructed data set to a reference set of material
signal amplitude and noise properties stored on a data storage medium;
e) classifying the voxels into air, low density or high density voxels;
f) based on the determination of e), selecting a first material decomposition
method to be applied to low density voxels and/or selecting a second material
decomposition method to be applied to higher density voxels;
g) applying a first material decomposition method to the low density voxels, the
first material decomposition method including using volume constrained non-
negative linear least squares to aid material identification; and/or
h) applying a second material decomposition method to the high density voxels, the
second material decomposition method including using an method that aids
material identification by enforcing a sparse representation of the material
composition for each voxel;
i) identifying specific materials with the object based on the solutions from g) and
h); and
j) presenting material identification information to an interface.
Preferably, the method includes the step of scanning an object using a multi-energy CT
system to produce an image data set and the step of sending the image data set.
Preferably, the step of classifying voxels as air, low density or high density voxels includes
comparing individual voxels to a reference distribution of a specific reference material using
the Mahalanobis distance metric and Euclidian distance metric.
More preferably, the step of classifying voxels further includes the step of filtering the data
to remove noise.
Preferably, the step of applying a second material decomposition method further includes
one or more of the steps as outlined in the eighth embodiment of the invention and the
subsequent preferred embodiments.
According to a fifteenth embodiment of the invention there is provided a system for
identifying and presenting a number of different materials represented by data produced by
a multi-energy CT system, the system comprising:
a) a means for receiving a reconstructed or non-reconstructed multi-energy CT
image data set in relation to an object;
b) a means for storing said data on a data storage medium;
c) a means for processing the data using one or more reconstruction techniques to
produce a data set of reconstructed voxels;
d) a means for comparing each voxel in the reconstructed data set to a reference
set of material signal amplitude and noise properties stored on a data storage
medium;
e) a means for classifying the voxels into air, low density or high density voxels;
f) a means for selecting a first material decomposition method to be applied to low
density voxels and/or selecting a second material decomposition method to be
applied to higher density voxels;
g) a means for applying a first material decomposition method to the low density
voxels, the first material decomposition method including using volume
constrained non-negative linear least squares to aid material identification;
and/or
h) a means for applying a second material decomposition method to the high
density voxels, the second material decomposition method including using an
method that aids material identification by enforcing a sparse representation of
the material composition for each voxel;
i) a means for identifying specific materials with the object based on the solutions
from g) and h); and
j) a means for presenting material identification information on an interface.
Preferably, the system includes a means for scanning an object using a multi-energy CT
system to produce a set of image data and a means for sending image data.
In preferred embodiments of the invention, the data is medical data and the low density
reconstructed voxels represent soft tissue.
In further preferred embodiments the data is medical data and the high density voxels
represent bone, implants, metals and/or contrasting agents.
According to a sixteenth embodiment of the invention there is provides a method for
identification or quantification of one or more components within, or excised from an
animal or human, the method including the steps of:
a) scanning the animal, human or part thereof using a multi-energy CT scanner to
produce an image data set or receiving a multi-energy CT image data set for the
animal, human or part thereof;
b) quantifying or identifying the one or more components based on the CT image data
set using any one or more of the computer implemented methods of the eighth and
fourteenth embodiments of the invention.
Preferably, the component to be identified or quantified is selected from plaque, cancer,
cancerous tumours or markers and biological identifiers thereof, components associated
with the inflammatory process or infection, bone or cartilage, pathogens, crystals, lipids or
fats.
Preferably, the method includes the step of administering a nanocontrast agent targeted to
the component to be identified to the animal, human or part thereof prior to scanning.
Preferably, the component to be identified is an atheroma or atherosclerosis plaque, or
components within an atheroma or plaque.
Preferably, the nanocontrast agents are selected from agents comprising nanoparticles of
one or more metals.
More preferably, the metals are selected from gold, gadolinium, iodine, hafnium, tantalum,
bismuth, ytterbium, platinum, yttrium and/or rubidium.
In further preferred embodiments, the nanocontrast agent further includes a biologically
active component.
More preferably the biologically active component is selected from a ligand, antibody or
part of an antibody.
Preferably, method includes a calibration step wherein known concentrations of the
nanoparticles are imaged and a calibration curve is generated.
In one preferred embodiment, the method includes quantifying components within ex-vivo
and in-vivo tissue. More preferably ex-vivo and in-vivo samples are quantified
simultaneously.
According to a seventeenth embodiment of the invention there is provided a method for
measuring drug penetration into animal tissue, the method including the steps of:
a) administering a nanocontrast agent targeted to drug to be identified within the
tissue;
b) scanning the tissue using a multi-energy CT scanner to produce an image data set;
c) quantifying the drug within the tissue based on the image data set using any one or
more of the computer implemented methods of the eighth and fourteenth
embodiments of the invention.
According to an eighteenth embodiment of the invention there is provided a method for
monitoring or identifying the presence of, or changes in specific tissue, tissues or
components in an animal or human including the steps of:
a) scanning the tissue or component using a multi-energy CT scanner to produce an
image data set;
b) quantifying the tissue(s) or components of interest within the animal or human
based on the image data set using any one or more of the computer implemented
methods of the eighth and fourteenth embodiments of the invention;
c) repeating steps a) and b) over a period of time to generate information identifying
the presence of, or changes in specific tissue, tissues or components over time; and
d) developing a treatment plan for the animal or human based on the information
provided from step c).
In preferred embodiments the method includes the step of administering a nanocontrast
agent targeted to the specific tissue or component prior to scanning.
In one embodiment the method includes monitoring one or more arteries to determine,
identify and/or manage the onset or progress of atherosclerosis.
In one embodiment the method includes monitoring cartilage health to determine, identify
and/or manage the onset or progress of cartilage degeneration.
In an alternative embodiment the method includes monitoring bone health to determine,
identify and/or manage the onset or progress of osteoarthritis or osteoporosis.
In an alternative embodiment the method includes monitoring a bone/implant interface to
determine, identify and/or measure the ingrowth of bone into the implant.
In a further alternative embodiment the method includes monitoring biomarkers of specific
cancers to determine, identify and/or manage the onset or progress of cancer.
In an alternative embodiment the method includes monitoring one or more specific markers
of an inflammatory cell to determine, identify and/or manage the inflammation or infection.
In further alternative embodiments the method includes monitoring one or more pathogens
to determine, identify and/or manage the pathogen and/or the pathogenic response.
According to a nineteenth embodiment of the invention there is provided a method for
determining bone and/or cartilage health in an animal or human, the method including the
steps of:
a) scanning the bone and/or cartilage using a multi-energy CT scanner;
b) quantifying the bone and/or cartilage within the animal or human based on the CT
data using any one or more of the computer implemented methods of the eighth
and fourteenth embodiments of the invention.
Preferably, the method of determining bone and/or cartilage health includes measuring or
quantifying one or more of bone densitometry, trabecular thickness and/or orientation
and/or spacing, collagen content in cartilage, fibrous tissue or bone, assessment of bone
cancer, or disease, infection or inflammation of bone or adjacent cartilage.
More preferably the measurement is bone densitometry of a bone or part thereof and the
method includes the step of determining the calcium hydroxyapatite concentration of the
bone or part thereof.
Even more preferably, the step of determining the calcium hydroxyapatite concentration
includes measuring the energy dependent Hounsfield units in the volume of bone or part
thereof, reading the corresponding hydroxyapatite concentration from a calibration curve
derived from measuring energy dependent Hounsfield units in a reference set of known
concentrations of hydroxyapatite.
Preferably, the method of determining bone and/or cartilage health also includes measuring
or quantifying bone densitometry, trabecular thickness and/or bone ingrowth to an implant
surface, at a bone-implant interface.
Preferably, the method of determining bone and/or cartilage health includes the step of
extracting molecular information relating to an ionic contrast agent and bone from an
anatomical joint.
More preferably, the method includes the steps of
a) injecting an ionic contrast agent into the joint space; and
b) acquiring multi-energy images of the cartilage-subchondral interface.
In one preferred embodiment the ionic contrast agent is selected from an iodine or
gadolinium based contrast agent.
According to a twentieth embodiment of the invention there is provided a method for
identifying and/or quantifying biomarkers of specific cancers in an animal or human, the
method including:
a) scanning a tissue or region of interest in an animal or human using a multi-energy CT
scanner to produce an image data set;
b) identifying and/or quantifying biomarkers within the animal or human tissue based
on the image data set using any one or more of the computer implemented methods
of the eighth and fourteenth embodiments of the invention.
Preferably, the method of detecting, localizing and/or quantify biomarkers of specific cancers
includes the further step of administering a nanocontrast agent to label specific tumour cell
markers and/or markers of the cellular immune response including macrophages, T cells, and
other immune response cell types at any tumour site, prior to the scanning step.
Preferably, the nanocontrast agent is or includes a functionalised nanoparticle.
Preferably, two or more different target components of the cancer are measured using a
single 3D volume scan.
Preferably, the method step of identifying and/or quantifying biomarkers includes the step of
quantifying specific drug delivery to a tumour site.
More preferably the method includes combining the drug or pharmaceutical with the
nanocontrast agent or separately labelling the drug with a metal marker.
According to a twenty-first embodiment of the invention there is provided a method for
identifying and/or quantifying pathogens in an animal or human, the method including:
a) scanning a tissue or region of interest in an animal or human using a multi-energy CT
scanner to produce an image data set;
b) identifying and/or quantifying pathogens within the animal or human tissue based
on the image data set using any one or more of the computer implemented methods
of the eighth and fourteenth embodiments of the invention.
Preferably, the method includes the step of administering to the animal or human two or
more different nanocontrast agents targeted to different potential pathogens, prior to
scanning, for imaging together in a single multi-energy CT scan.
According to an twenty-second embodiment of the invention there is provided a method for
determining the growth of tissue associated with an implanted scaffold or engineered tissue
in an animal or human, the method including:
a) scanning a tissue or region of interest in an animal or human using a multi-energy CT
scanner to produce an image data set;
b) identifying and/or quantifying the growth of tissue associated with an implanted
scaffold or engineered tissue within the animal or human based on the image data
set, using any one or more of the computer implemented methods of the eighth and
fourteenth embodiments of the invention.
More preferably, the method further includes one or more of the steps of:
- identifying the implanted scaffold or engineered tissue within the animal or human;
- quantifying the type and/or quantity of new tissue associated with the scaffold or
engineered tissue; and/or
- determining the resorption of the scaffold or engineered tissue.
Even more preferably, the step of identifying the implanted scaffold or engineered tissue
includes identifying a material from which the scaffold or engineered tissue is made or
identifying a material eluting from a scaffold or engineered tissue.
Even more preferably, the step of quantifying the type and quantity of new tissue
associated with the scaffold or engineered tissue includes targeting specific cells or tissue
types with nanocontrast agents prior to imaging.
More preferably the nanocontrast agent is delivered to the target cells or tissues by
injection, topical application, or by incorporation within an implantable scaffold or stent.
Preferably, the method includes the further step of routinely determining the growth of
tissue associated with an implanted scaffold or engineered tissue over a period of time and
determining the success or likely success of the implanted scaffold or tissue based on the
growth of the associated tissue.
According to an twenty-third embodiment of the invention there is provided a method for
identifying and/or quantifying intracellular or extracellular lipid in the body or an animal or
human, the method including:
a) scanning a tissue or region of interest in an animal or human using a multi-energy CT
scanner to produce an image data set;
b) identifying and/or quantifying intracellular or extracellular lipid within the animal or
human based on the image data set, using any one or more of the computer
implemented methods of the eighth and fourteenth embodiments of the invention.
Preferably, the method includes identifying and/or quantifying myelination or intra-tumoral
lipids.
According to an twenty-fourth embodiment of the invention there is provided a method for
identifying and/or quantifying pore sizes in animal of human tissue, the method including:
a) scanning a tissue or region of interest in an animal or human using a multi-energy CT
scanner to produce an image data set;
b) identifying and/or quantifying pore sizes within tissue or region of interest in the
animal or human based on the image data, using any one or more of the computer
implemented methods of the eighth and fourteenth embodiments of the invention.
Preferably, the method includes quantifying pores size by administering to an animal or
human nanomaterials of one or more sizes and measuring nanoparticle content at a region
of interest.
Preferably, the pore sizes measured are selected from pores in the liver, spleen, blood
vessels or blood-brain barrier.
Preferably, method includes performing multi-energy CT imaging 12 – 36 hours following
administration of nanoparticles to the animal or human. More preferably the imaging is
performed 18 – 24 hours after administration of the nanoparticles.
According to an twenty-fifth embodiment of the invention there is provided a method for
detecting and identifying benign and/or malignant breast diseases in an animal or human,
the method including:
a) scanning a tissue or region of interest in an animal or human using a multi-energy CT
scanner to produce an image data set;
b) identifying and/or quantifying benign and/or malignant breast diseases within tissue
or region of interest in the animal or human based on the image data set, using any
one or more of the computer implemented methods of the eighth and fourteenth
embodiments of the invention.
Preferably, the method further includes one of more of the following steps:
- identifying and/or quantifying lipid of fat within the breast;
- identifying and/or quantifying microcalcifications within the breast;
- administering to the animal or human targeted nanocontrast agents specific to
breast tumour target cells prior to imaging, then identifying and/or quantifying the
agent within breast tissue post imaging.
In one preferred embodiment the nanocontrast agents are targeted to oestrogen receptors
or HER-2 receptors.
According to a twenty-sixth embodiment of the invention there is provided a method for
measuring activation of a pro-drug in an animal or human, the method including the steps
a) labelling an active component of the pro-drug with a first nanocontrast agent;
b) labelling an inactive component of the pro-drug with a second nanocontrast agent;
c) administering the labelled pro-drug to the animal or human prior to imaging;
d) performing a first scan of the target area in the animal or human using a multi-
energy CT scanner to produce an image data set;
e) determining the presence of and if present, measuring the inactive and active
components of the pro-drug at the target area based on the image data set using
any one or more of the computer implemented methods of the eighth and
fourteenth embodiments of the invention;
f) after a pre-determined period of time, performing a second scan of the target area
in the animal or human using a multi-energy CT scanner to produce a second image
data set; and
g) determining the presence of and if present, measuring the inactive and active
components of the pro-drug at the target area based on the second image data set
using any one or more of the computer implemented methods of the eighth and
fourteenth embodiments of the invention;
wherein the presence of the active component and absence of, or decrease in the
quantity of the inactive component at step g) indicates drug activation.
According to a twenty-seventh embodiment of the invention there is provided a method for
identification or quantification of a component within, or excised from an animal or human,
the method including the steps of:
a) scanning the animal, human or part thereof using a PET or SPECT scanner;
b) using the results of step a), identifying a region of interest within the animal or
human;
c) administering a nanocontrast agent to the animal or human targeted to the region of
interest or drug to be delivered to that region;
d) scanning the animal or human using a multi-energy CT scanner to produce an image
data set; and
e) quantifying the nanocontrast agent based on the image data set using any one or
more of the computer implemented methods of the eighth and fourteenth
embodiments of the invention.
Preferably, the region of interest is a residual cancer site and the nanocontrast agent is
targeted to determine drug delivery to the residual cancer site.
Further embodiments of the invention, which should be considered in all their novel
aspects, will become apparent to those skilled in the art upon reading of the following
description which provides at least one example of a practical application of the invention.
For the purposes of this application the terms “low density voxels” and “high density voxels”
should be taken to mean voxels containing low atomic number materials and high atomic
number materials respectively.
“Soft tissue” items are low (radiographic) density and the definition includes tissue such as
adipose tissue, brain (grey/white matter), skeletal muscle, lung tissue and blood, lipids and
water. These examples of soft tissue contain a very high fraction of low atomic number
atoms, largely organic molecules. Soft tissue of contains low levels of salts, such as NaCl or
KCl. These are in relatively small amounts and are not of levels high enough to make
significant contribution to the radiographic density, or to the mass density.
“Image data” is defined as any data directly or indirectly derived from one or more x-ray
detectors of a multi-energy CT system. It typically consists of, but is not limited to, numbers
(counts, or other brightness measures) for some or all the energy ranges of the multi-energy
capabilities of the x-ray detector(s).
An “Image data set” refers to a full set of data, including numbers for every pixel, for every
projection image of a particular object being scanned. Without loss of generality, the term
“image data set” as used within the specification includes both a full set of image data, or
any subset of a full set of image data.
Example of high density materials are bone, cartilage, implants or scaffolds implanted into
the body, and metals or heavy metals, including those forming part of nanocontrast agents
such as gold, gadolinium, iodine, hafnium, tantalum, bismuth, ytterbium, platinum, yttrium
and/or rubidium as a selection of non-limiting examples.
It should be noted that multi-energy CT is often called spectral CT to distinguish it from the
original dual-energy modalities. However it has now become commonplace to also refer to
dual-energy as spectral. To avoid any confusion that may occur we have refrained from
using the term “spectral” where possible. In place of this we use dual-energy to specifically
refer to the dual-energy modalities, and we use the term multi-energy to refer to both dual-
energy CT and modalities of CT capable of measuring more than two energy ranges such as
the MARS scanner.
Brief Description of the Drawings
One or more embodiments of the invention will be described below by way of example only,
and without intending to be limiting, with reference to the following drawings, in which:
Figure 1 shows (a) An example of a 95% confidence interval (shaded region) for a
univariate Gaussian distribution and (b) An example of a 95% confidence
ellipsoid (inside the blue ellipse) for a bivariate Gaussian distribution;
Figure 2 shows a computer implemented method for selection of a decomposition
method in one embodiment of the invention;
Figure 3 shows a simulated phantom containing a variety of soft tissue and dense
materials. Each material region is 100 × 100 voxels in size and surrounded by
air;
Figure 4 shows a simulated phantom containing a variety of soft tissues and dense
materials, each material region being 100 x 100 voxels in size and surrounded
by air.
Figure 5 shows a simulated phantom with two different levels of white Gaussian noise
added, SNR =10 and SNR = 20;
Figure 6 Ideal segmentation outcome and the segmentation results for SNR = 10 and
SNR = 20;
Figure 7 shows the percentage of air voxels correctly assigned during segmentation
for varying numbers of energy bands and levels of SNR;
Figure 8 shows a multi-energy CT scan of lamb meat phantom. The top PCR tube
(circle) contains a KI solution and the bottom PCR tube contains a CaCl2
solution;
Figure 9 shows the material classes produced by SST algorithm applied to lamb meat
phantom reconstruction. Material decomposition image also included
(bottom right) - artificial colouring used in material decomposition image:
lipid = yellow, water = red, calcium (bone) = grey, and iodine = green;
Figure 10 shows objective function contours (red) from minimizing a residual vector ~w
using the 0-norm, 1-norm and 2-norm.
Figure 11 shows a computer implemented method for the identification of materials
within an object method in one embodiment of the invention;
Figure 12 shows a multi-contrast phantom layout with capillaries containing solutions
of five different materials: Au nano-particles, MagnevistTM (gadolinium) and
OmnipaqueTM (iodine) contrast pharmaceuticals, CaCl2, and water;
Figure 13 shows a multicontrast phantom slice 12 following algebraic reconstruction;
Figure 14 shows the combinatorial material decomposition of a multi-contrast
phantom, with the scale for each material in g/ml;
Figure 15 shows the representations of multi-contrast phantom CMD decomposition
comparing soft tissue and dense material;
Figure 16 shows the linear least squares material decomposition of multi-contrast
phantom, with the scale for each material in g/ml;
Figure 17 shows the non-negative linear least squares material decomposition of multi-
contrast phantom, with scale for each material in g/ml;
Figure 18 shows the MARS-MD material decomposition of multi-contrast phantom,
with the scale for each material in g/ml;
Figure 19 shows a computer implemented method for the identification of materials
within an object method in a further embodiment of the invention;
Figure 20 shows a representation of one embodiment of a system for implementing
any one or more of the methods shown in Figures 2, 11 or 19;
Figure 21 shows a representation of an alternative embodiment of a system for
implementing any one or more of the methods shown in Figures 2, 11-13 or
Figure 22 shows representations of multi-contrast phantom MARS-MD decomposition;
Figure 23 shows material decomposition concentrations compared to the known
concentrations of each dense material;
Figure 24 shows a FatCaFe dataset and associated material decompositions using both
CMD and MARS-MD;
Figure 25 shows material decomposition images of an atherosclorosis plaque;
Figure 26 shows a photo of atherosclerotic plaque prior to scanning, 3D material
decomposition image of plaque, and reconstructed Hounsfield unit image of
plaque;
Figure 27 shows a reconstructed Hounsfield unit image and material decomposition
images of an excised arthritic human tibial plateau incubated in iodine
contrast;
Figure 28 shows a 3D material decomposition image of an excised arthritic human tibial
plateau incubated in iodine contrast; and
Figure 29 shows a 3D material decomposition of “Mouse 12” dataset reprocessed using
the methods of the present invention.
Detailed Description of Preferred Embodiments of the Invention
The invention generally relates to the methods for identification and quantification of a
number of different materials within an object using one or more multi-energy CT imaging
devices and the image data sets produced therefrom. The invention also relates to one or
more computer program products, computer systems or computer implemented methods
for the identification of multiple materials within an object.
One embodiment of this invention discloses a material quantification algorithm which will
be discussed below as the “MARS-MD” or “MARS-MD algorithm” or “MARS-MD program”.
The purpose of this algorithm is to identify large numbers of different materials
simultaneously from data collected by a multi-energy CT scanner. In summary, this is
achieved by using the following three properties: solve only for sparse solutions; separate
the soft tissue problem from the dense material problem; and use a combinatorial approach
to allow for simple application of different constraints to different combinations of
materials. It is shown that this algorithm may easily decompose six different materials using
four energy bands.
A more detailed discussion of the methods developed is given below with reference to the
use of the methods for the purposes of medical imaging of human tissues. This application is
not intended to be limiting, and it is envisaged the techniques and methods discussed
herein may be applied to a wide range of applications, both within the medical field and
outside of it. More specifically, the methods described below relate to the imaging of
human tissue in various applications, with reference to Figures 1 – 29.
MARS-MD is a material quantification algorithm for processing multi-energy CT datasets
produced by one or more multi-energy CT scanners. The overall material decomposition
algorithm of the present invention first uses a statistical segmentation technique (SST)
algorithm to determine whether a reconstructed voxel is either low density material or high
density material which will then determine the type of material decomposition algorithm
used for that voxel.
Following the application of the SST algorithm, voxels containing low density material will be
decomposed into lipid and water using volume constrained non-negative least squares.
Voxels with high density material will be decomposed using a new method which will be
referred to herein for the purposes of the description only as the combinatorial material
decomposition (CMD) or “CMD algorithm”. The full material matrix used by the MARS-MD
program has been experimentally determined using scans of phantoms with known
composition.
The first algorithm used within in the MARS-MD algorithm is referred to as the SST
algorithm. Multi-energy CT data not only contains intensity information in the relative
differences in attenuation between materials, it also contains spectral information from the
differences in attenuation across energy. The segmentation technique described herein
separates multi-energy CT data based on both spectral and intensity information. The SST
algorithm uses confidence ellipsoids to analyse spectral information.
The aim of this segmentation procedure is to identify each voxel as one of three material
classes: either air, low radiographic density, or high radiographic density. When applied to
medical imaging as in the example given in the description, the voxels may be identified as
air, soft tissue or dense voxels. For other applications other density related characteristics
related to the specific materials within the voxels may be used.
When using the present invention for medical purposes, soft tissue is assumed to be
primarily composed of lipid, water and protein such as adipose tissue, muscle, blood or
cartilage. Radiographically dense materials are considered to be bone, metal or tissue
containing contrast pharmaceuticals. These groups of materials have been chosen since the
linear attenuation for air is strictly less than that for soft tissues and the linear attenuation
for soft tissues is strictly less than that for dense materials.
SST breaks the segmentation process into two parts. The first stage of SST compares each
voxel to the boundary materials of the soft tissue material class using the Mahalanobis
distance metric. All voxels found to be within the 95% confidence ellipsoid of either
boundary materials are preferentially assigned to the soft tissue class as they are considered
to be spectrally identical. Any voxel found to be outside both 95% confidence ellipsoids are
assigned based on comparing their Euclidean norms to that of the boundary materials: if
less than lipid then the voxel is assigned to air; if between lipid and water then is assigned to
soft tissue; and if greater than water then is assigned to dense materials.
In statistics, a confidence interval is a range of values that measurements from a given
distribution can be considered reliable for a given confidence level. If the interval has a
confidence level of 95%, then 95% of all measurements taken from that distribution would
be expected to be contained within that confidence interval, as shown in Figure 1.
It is typically not sufficient to approximate a multi-variate data with a collection of uni-
variate
confidence intervals. This is because as well as having variance in each variable there is also
covariance between variables. To consider the effect of covariance, the confidence interval
needs to be replaced by a confidence ellipsoid, shown as (b) in Figure 1. A measurement is
found to be inside a confidence ellipsoid if the Mahalanobis distance between the
measurement and the mean of the distribution it was sampled from is less than or equal to
the value of the χ distribution for the associated confidence level.
The Mahalanobis distance metric, D (x, μ), is a measure of how close a measurement x
from a distribution is to the distribution mean μ, taking into account correlations in the
data. For a multivariate normal distribution with covariance Σ, the Mahalanobis distance
between any measurement x and the distribution mean μ, is given by
D (x, μ) = (x – μ) Σ(x – μ)
The second stage of SST is the application of a median filter to each of the air / soft-tissue /
dense images obtained above. This is required as the allocation process in the first stage will
typically contain salt and pepper noise. The covariance matrix used in the calculation of the
Mahalanobis distance in SST is obtained by sampling a homogeneous region of air in a single
slice of the volume. It is assumed that this matrix is representative of the covariance matrix
for the entire volume.
The Statistical Segmentation Technique Algorithm can be represented as below (ALG 1.0),
where represents binary images for each material class, µ represents linear attenuation
and represents a linear attenuation vector.
The SST algorithm 100 as applied to a computer program product is summarised in Figure 2.
In the method described in Figure 2, image data from a multi-energy CT scan is received by a
processor. It is envisaged that multi-energy CT image data may be generated from a
scanning system directly linked to the processing system, or received from a remote
location via a network. Image data is received by processor 410 then if non-reconstructed, is
reconstructed with algorithm 425 using known data reconstruction techniques, for example
an algebraic reconstruction technique, to produce a set of reconstructed voxels.
Reconstructed voxel data is then compared to a reference set of material signal amplitude
and noise properties 430 stored in a database and the voxels then classified into air, low
density or high density voxels 440 based on comparison with the reference set.
Based on the determination of voxel density during the classification step, a first material
decomposition method is selected to be applied to low density voxels and a second material
decomposition method is selected to be applied to higher density voxels 450. Information
regarding the selection of the appropriate decomposition method is communicated to an
interface 460. In preferred embodiments of the invention the interface is an application
program interface (API) although a range of other known interfaces are encompassed by the
scope of the invention, including, but not limited to user interfaces, software and hardware
interfaces.
A simulated phantom was used to investigate how the SST algorithm worked with a range of
different tissues and for images with different signal to noise ratio (SNR). The simulated
phantom can be seen more clearly in Figure 3. The simulated phantom contained a range of
soft tissue materials including adipose tissue, brain (grey/white matter), skeletal muscle,
lung tissue and blood (whole). These along with lipid and water are the phantom’s soft
tissue class materials. Dense materials chosen for the phantom include cortical bone along
with various concentrations of Iohexol™ (iodine) and Gadodiamide™ (gadolinium) solutions -
which are commonly used as part of commercial contrast pharmaceuticals. Each material
region in the simulated data is 100 × 100 voxels in size.
The upper segmentation boundary (μwater in Alg. 1.0) was chosen to be μblood as it is the
highest
attenuating soft tissue of those selected. The lower segmentation boundary was chosen to
be μ . Six subtracted energy bands were constructed from a simulation of a 120 kVp
lipid
tungsten x-ray spectrum passing through 12mm Al filtration. The effective lower boundaries
of these energy bands are 30.4, 37.0, 45.5, 56.1, 68.2 and 92.9 keV. In addition the effective
upper boundary of all these energy bins is 120keV. Linear attenuation coefficients for each
material at each effective energy band were obtained from the NIST XCOM database, a web
database produced by the National Institute of Standards and Technology, currently
available at www.nist.gov.
Figure 4 shows a simulated phantom containing a variety of soft tissues and dense
materials, each material region being 100 x 100 voxels in size and surrounded by air.
The SST algorithm was tested at six different levels of SNR - 10, 20, 30, 40, 50, and 60. This
was done by adding white Gaussian noise to the simulated dataset. Figure 5 shows the 30.4
to 37.0 keV image for SNR of 10 and 20.
Results
It was found that there is greater than 99.99% correct voxel assignment for all SNR values
tested apart from an SNR of 10. As shown in Figure 5, the test with an SNR of 10 allocated
air voxels to the soft tissue class. Figure 6 shows the ideal segmentation outcome results for
SNR = 10 and SNR = 20. It is seen that air is incorrectly allocated to the soft tissue class for
SNR = 10, whereas SNR = 20 provides near perfect segmentation.
The allocation of voxels to the wrong material class in the SST algorithm was investigated.
This
was tested using samples of 9216 simulated air voxels (assumed to have zero effective
attenuation) and white Gaussian noise added with SNR ranging from 10 to 20 (in steps of
one). This SNR range was chosen due to the previous section’s results suggesting the SNR
limit for the algorithm’s success lies within this range. Two tests were performed:
1. Measuring the percentage of air voxels assigned to the correct material class when two
different parameters are varied - the number of energy bands (ranging from 1-6) and the
SNR of the energy bands (ranging from 10-20). All energy bands in the given number of
energy bands and SNR level each have the same SNR.
2. Determining the effect that using energy bands at different levels of SNR has on the
segmentation.
Starting with a fixed number of energy bands each with the same SNR (chosen to be 5
energy bands with SNR = 16), add another energy band to the segmentation with and SNR
ranging between 10 - 20. The purpose of these tests is to find both the minimum SNR for
successful segmentation, and to determine how this minimum changes when different
quality spectral information is used (i.e. different numbers of energy bins and different
levels of noise in each energy bin).
The results from the first test shown in Figure 7 indicate that if more energy ranges are
included in the segmentation (assuming identical SNR) then more voxels will be assigned
correctly at lower SNR levels. There is a significant difference in performance when moving
from using no spectral information (1 energy band) to using spectral information (2+ energy
bands). The degree of improvement from each additional extra energy added however
decreases as more energy bands are included.
The second test showed that when an extra energy band is added to the segmentation the
following is observed: If the added energy band has higher SNR than the other energy bands
then the segmentation is improved - as would be expected; if it has lower SNR then the
segmentation will typically be worse. There is however a buffer region where the benefit of
including another energy band is greater than the negative effects of that energy band
having lower SNR (if the difference in SNR between the new and other energy bands is small
enough), which will result in an improved segmentation.
Example Using SST
A phantom was made with lamb meat, bone and PCR tubes containing CaCl2 and KI
solutions.
The phantom was then scanned with a MARS multi-energy CT scanner equipped with a CdTe
Medipix-3RX detector operating in charge summing mode. The acquisition simultaneously
measured four energy ranges: 14.7−80 keV (shown as 71 in Figure 8), 19.7−80 keV (72),
32.8−80 keV (73) and 44.8−80 keV (74). Each energy range was reconstructed separately
using an algebraic reconstruction technique and the resulting images shown in Figure 8.
The SST algorithm was applied to the reconstructed lamb meat phantom data during
material
analysis. Each different material in the sample was mostly found to identify with the
appropriate material class as shown in Figure 9, which shows a soft tissue class map 80,
dense tissue/contract class map 81, air class map 82 and material decomposition 83. The
main exception to this is in regions containing significant artefacts, for example the ring
artefact 84 which is clearly visible in the soft tissue class map 80. The result of material
decomposition (using the algorithm presented later in the description) is also shown in
Figure 9 at 83.
It is evident from the results in Figure 7 that the segmentation algorithm can manage noisier
data when multi-energy data (instead of single-energy) is used. This demonstrates that
there is much benefit to be gained from integrating spectral information into segmentation
techniques used in multi-energy x-ray imaging.
The simulations that are presented here analyse how the algorithm performs with simple
Gaussian noise. Real world measurements however are corrupted with many different types
of noise, for example electrical noise and ring artefacts. The segmentation of the lamb meat
phantom is provided to show that this algorithm also performs reasonably well with real
data.
Combinatorial Material Selection
It is well established that the method of ordinary linear least squares, when used for
material decomposition, does not perform well when attempting to decompose data into a
large number of materials. This poor performance is in part due to the similarities between
the attenuation properties of materials which are typically of interest in this problem (e.g.
lipid, water, protein, bone, metal and iron). Including many such materials into the material
decomposition problem results in a material matrix which has a high condition number (i.e.
is close to singular) and therefore is typically too ill-conditioned to solve using ordinary
linear least squares.
To overcome this limitation, extra information or approximations about the data are
generally
used. Some examples of these include: adding constraints for either volume or mass
conservation within voxels; using an estimate of the data’s covariance matrix to add further
stability to the inversion; and assuming that there is a maximum number of materials per
voxel, a number that is less than the number of materials in the material matrix (this also
known as a sparse solution).
Disclosed below is an algorithm that uses a combinatorial approach to finding a sparse
solution to the material decomposition problem. For the purposes of this specification this
algorithm will be referred to as the combinatorial material decomposition or CMD
algorithm.
First a brief introduction is given to sparse solutions to problems and how they are found.
Then the combinatorial material decomposition algorithm will be disclosed. Finally analysis
of a “six material four energy” material decomposition of experimental data using the
combinatorial material decomposition algorithm is presented.
Finding sparse solutions
Suitable solutions to the material decomposition problem are typically sparse. For example,
if a
material basis contains four materials (bone, lipid, water and iodine) then a voxel
representing
bone is described using only one of the four basis materials (i.e. bone) and a voxel
representing
iodine pharmaceutical in blood will be well described using two of the basis materials (i.e.
water and iodine).
A solution to a problem is said to be sparse if the number of basis elements required to
describe the solution is less than the total number of elements in the basis. This can be
described more formally by the following: given a basis B with N elements
(4.2)
a measurement f is said to have a sparse representation in that basis if the number of non-
zero
coefficients a in the decomposition of f into that basis is less than N, where
(4.3)
If f(B) has k < N non-zero coefficients then f is said to be k-sparse in B .
When determining which method is suitable for solving a given problem (such as material
decomposition) it is important to know if desired solution should be sparse. This is because
various techniques, such as least squares, favour finding non-sparse solutions. This concept
of a technique of preferentially finding either a sparse or non-sparse solution is shown in
Figure 10.
This example shows the result of minimizing a residual vector w using three norms. The
thick grey lines represents constant value of the objective function (also known as objective
function contours or p-norm balls) and the thin grey diagonal line represents all feasible
solutions to the problem. If the objective function contour is blown up (i.e. the value of the
objective function is increased) then where it first hits the diagonal line of feasible solutions
is the solution that is found by solving the optimization problem with the given norm. It can
be seen from this example that techniques such as least squares will almost never provide a
sparse solution, where as minimizing the equivalent 0-norm or 1-norm problems will almost
always provide a sparse solution.
Minimisation problems using these sparsity promoting norms are typically associated with
compressed sensing (or compressive sampling). This class of techniques is well known for its
achievement of overcoming the Nyquist sampling rate limitations of classical signal
processing techniques. They also have applications in image and signal de-noising.
Compressed sensing works by transforming a non-sparse signal into a space where it has a
sparse representation (for example - using a wavelet transform). The given problem (such as
de-noising) is then solved in the transform space as a sparse optimization problem using
either the 0-norm or 1-norm. Using the 0-norm for optimization is usually avoided as it is a
non-convex problem requiring combinatorial methods to solve (of which the length of time
required is infeasible in applications dealing with large systems). The 1-norm is preferred
over the 0-norm for compressed sensing as it provides a convex optimization problem.
Figure 10 shows objective function contours from minimizing a residual vector w using the
0-norm, 1-norm and 2-norm. The solution returned by the respective minimization is given
where the contour touches the line of feasible solutions. Sparse solutions are promoted by
using 0-norm and 1-norm minimization, whereas 2-norm minimization will rarely produce
sparse solutions.
Combinatorial Material Decomposition (CMD) algorithm
The combinatorial material decomposition (CMD) is an algorithm developed by the
inventors which uses 0-norm minimization to achieve sparse solutions. The 0-norm was
considered ideal for sparse material decomposition for the following reasons: having to
check each combination of materials enables non-physical solutions and solutions with
unlikely combinations of materials to be explicitly rejected; and each voxel in material
decomposition is treated as an independent problem with few variables, therefore it does
not take an unreasonably long time to calculate the desired sparse material combinations.
The CMD algorithm (Alg. 2.0 below) is best described in two parts, first the calculation of
sparse solutions for the data set and then the solution rejection criteria used to remove
non-physical solutions.
Calculating Sparse Solutions
As stated earlier, given a voxel in a reconstructed multi-energy CT scan b the system of
equations required to be solved for material decomposition is Mx = b where M is the
material matrix containing N materials and x is the vector describing the composition of the
voxel.
The sparse solutions problem being solved in CMD is given by;
(4.4)
where k is the maximum level of sparsity (number of materials) allowed in the solution and
k < N.
This problem is solved by first determining all combinations of k and fewer materials
represented by the material matrix. For each combination a reduced material matrix M is
constructed using the respective materials, then the non-negative linear least squares
solution x is calculated for the sub-problem M x = b. The solution which has the smallest
r r r
least square error out of all the tested combinations is then selected as the best solution.
A clear advantage of this algorithm is that the success of the problem is limited by material
sparsity rather than the number of energy bands. By this we mean that if you have for
example two energy bands (dual-energy) then standard least squares (without constraints
such as mass conservation) limits the material matrix to two materials before it is under-
determined (or rank deficient). However, with this type of algorithm it is the “reduced
material matrices” that are used in the least squares procedure, and therefore it is the
“reduced material matrices” that are limited to two materials (i.e. the maximum level of
sparsity). This means that the CMD algorithm can have a full material matrix with more
materials than energies without ever having to deal with the problems associated with
under-determined non-square matrices.
Solution rejection criteria
As stated above, using a combinatorial algorithm enables an easy method to reject solutions
which either are non-physical or consist of an unlikely combination of materials. The CMD
algorithm described below (Alg. 2.0) is given by the base formulation above combined with
the following two rejection criteria:
1. Combinations of materials which are pre-determined not to be found in the same voxel
automatically rejected. For example it would be expected that bone would generally not
be found in the same voxel as soft tissue or iodine intra-vascular contrast, therefore those
combinations can be rejected.
2. An acceptable solution range is set for each material, any sub-problem with a solution
substantially outside of these ranges is automatically rejected. For example, the density of
bone does not vary wildly from 1.9 g/ml therefore if a solution found to be 0.02 g/ml or 10
g/ml it could be assumed to be non-physical and rejected. Another important example for
this rejection criterion is for contrast pharmaceuticals, where the lowest acceptable solution
can be set to be the lowest detectable concentration that is measurable by the given multi-
energy CT system.
Algorithm 2.0 Combinatorial Material Decomposition (CMD)
The CMD algorithm can be used for material decomposition of experimental data into six
materials using only four energy bands. For comparison, the CMD result is compared to
results obtained from using linear least squares and non-negative linear least squares
material decomposition methods (with the same data and material basis).
The CMD algorithm in use as implemented by a computer software program can be seen in
by method 700 in Figure 11. The methods described here may be carried out on one or
more of the systems as shown in Figures 20 and 21 and described in further detail below.
As seen in Figure 11, a multi-energy CT image data set is received by a processor 710. It is
envisaged that the image data set may be generated within a system incorporating the
processor described herein, or received over a network from an external system.
At 715 excluded material combinations in the data set that are pre-determined to be
disallowed are defined.
At 720 the processor then calculates, for each of the reconstructed voxels contained within
the data, a sparse solution for a maximum number of material combinations using a least
square (I2 norm) minimisation subject to a 0-norm constraint inequality for enforcing a
maximum number of materials per voxel by combinatorial search over the not excluded
material combinations during the least squares minimisation.
Rejection criteria is applied 730 to the sparse solutions 720 while performing the
combinatorial search to identify one or more materials, the rejection step includes setting
acceptable solution ranges for each material, and rejecting any sub-problem with a solution
outside these ranges.
Following rejection of unsuitable data solutions, materials represented by the image data
are determined 740 and the resulting information presented to a user interface 750.
Examples of such user interfaces include graphical user interfaces or visual user interfaces
including one or more monotone (grey scale or single colour) images, where the intensity is
proportional to quantity in a voxel; and multi-colour images with different colours
representing different materials.
The transform from the mathematical solutions to the material-quantified CT image can be
obtained by, for example, allocating each material to a specific colour or a separate image. A
2D grey scale image is naturally described by a matrix of numbers proportional to the
brightness of each pixel. Since the CMD algorithm constructs matrices of the contents of
voxels, one for each of the basis materials, any 2D slice of the volume gives a matrix that can
be displayed, one image per material. A set of such images can be visually represented by
specific and distinctive colours, and if the solution is sufficiently sparse, the different
coloured images combined into a single multi-colour image.
An example of the CMD algorithm outlined by Figure 11 is given below.
Multi-contrast phantom dataset
A multi-contrast phantom consisting of a solid polymethyl methacrylate (PMMA) cylinder
with
four capillaries drilled in the middle and eight around the outer edge was prepared. Samples
contained in small polymerase chain reaction tubes (PCR tubes) were inserted into each of
the capillaries. Solutions for these capillaries are shown in Figure 12 and include Au nano-
particles at 2, 4, and 8 mg (Au)/ml; Magnevist™ (gadolinium based contrast pharmaceutical)
at 2.1, 4.2, and 8.4 mg (Gd)/ml; Omnipaque™ (iodine based contrast pharmaceutical) at 9,
18, and 36 mg (I)/ml; CaCl2 at 140, and 280 mg (Ca)/ml; and water.
The phantom was scanned using a CdTe-Medipix-3RX camera operating in charge-summing
mode and a 120 kVp tungsten x-ray tube. Four energy bands were acquired at ranges of 27
– 120 (110 on Figure 11), 33−120 (111), 55−120 (112), and 81−120 (113) keV. Each energy
band was reconstructed independently using an algebraic reconstruction technique. Slice 12
of the reconstruction is shown in Figure 13.
The basis for material decomposition consisted of effective mass attenuation coefficients
calculated from the reconstructed images. Six materials were chosen: the five capillary
materials - calcium, gadolinium, gold, iodine, and water (using the median of 1920 voxels
each); and the PCR tube plastic was chosen for an estimate for lipid (using the median of
420 voxels).
The CMD algorithm was used for material decomposition into the six material basis using
only the allowed combinations of materials: lipid and water, individual dense material
(calcium, gadolinium, gold, and iodine), and dense material with water. No bounds were
placed on the solution range (i.e. an allowed range of 0 ∞ for each material). The data
for each energy range was de-noised prior to decomposition by averaging together five
adjacent images and applying a cylindrical median filter with a circle radius of 1 voxel (2
voxels for the 81 − 120 keV band).
The material decomposition result, shown in Figure 14, has performed well by identifying all
dense materials and water in the capillaries. A significant proportion of the PCR tube was
also identified correctly in the lipid image. PMMA however was identified mostly as pure
lipid with a density of 1.5 g/ml which is a non-physical result (pure lipid typically has a
density in the range 0.90 − 0.95 g/ml). There was also a minor misallocation of dense
materials across the image, the most prominent being gadolinium in PMMA. A
representation of the decomposition is provided in Figure 17, showing soft tissue 130 and
dense material 131.
Moore-Penrose Pseudo Inverse and Non-negative Linear Least Squares
For comparison, material decomposition on the same data was performed using two basic
methods, linear least squares and non-negative linear least squares. Linear least squares
+ T )−1 T
was performed using the Moore-Penrose pseudo inverse M = (M M M . The material
matrix used in both of these decompositions consisted of all six materials mentioned above
(and 4 energies) used in the CMD decomposition. The results of these two methods are
shown in Figures 16 and 17.
Figure 16 shows the results of the Moore-Penrose psuedo inverse (linear least squares) for
each of the six materials used.
Figure 17 shows the results of the non-negative linear least squares analysis for each of the
six materials used.
It is clear from these results that both methods are unable to identify all six materials
simultaneously. The linear least squares method both has highly negative results for some
materials, and each voxel is given a significant allocation of almost every material (resulting
in a copy of the entire phantom shown in each material image). However, this result is not
surprising since the material matrix has fewer rows than columns. The non-negative linear
least squares has performed slightly better than linear least squares at separating the lipid-
water like part of the signal from the dense material part of the signal, however there is still
significant mismatch between the dense materials.
The combinatorial material decomposition algorithm presented in this section is designed to
material identification by enforcing a sparse representation of the material composition for
each voxel. CMD does this by taking a large ill-conditioned material matrix and breaking it
up into a set of smaller better conditioned material matrices, which are better suited for
inversion. This method enables multi-energy CT data to be decomposed into a great number
materials using few energy ranges, without inclusion of the volume or mass fraction
conservation constraints.
The decomposition on the multi-contrast phantom using CMD, as seen in Figure 14, shows
that a reasonable six material decomposition with four energy bands can be achieved by
enforcing a limit on the total number of materials allowed in a voxel. Minor misallocation of
materials is observed (particularly in the lipid and gadolinium material images), however in
general all material regions are well distinguished.
When compared to the results of the linear least squares and non-negative linear least
squares decompositions, which significantly fail to separate any single material, the CMD
result can be considered a success.
An advantage of the CMD algorithm structure is that further constraints can easily be
enforced on individual material combinations. For example using either volume/mass
fraction conservation or allowed solution ranges. Additional constraints can reduce the
amount of material misallocation to improve the accuracy of the decomposition. The use of
additional constraints will be shown in later in the description with the MARS-MD algorithm.
The CMD allowed concentration range for each material was not set in the above multi-
contrast phantom example so as to demonstrate the potential of using algorithms for
material decomposition that find sparse solutions. This constraint was originality devised to
constrain calcium to the concentration range of bone to pre-empt any problems which may
occur when comparing materials such as lipid, water and calcium (which do not have a K-
edge in the diagnostic imaging range). In practice, this constraint only ever needs to be set
when testing the algorithm on data with a high degree of noise.
The MARS-MD Algorithm
The MARS-MD algorithm uses SST to separate low attenuating soft tissue materials from
high attenuating dense materials, enabling each case to be decomposed using a different
material decomposition algorithm. The motivation for this approach is that suitable
algorithm constraints can be picked specifically for each group of materials. For example,
the volume conservation constraint is a good approximation for soft tissues (which is
primary composed of lipid and water) but is violated for high concentrations of contrast
pharmaceuticals (where the density of water changes due to electrostatic forces exhibited
from heavy atoms in the contrast). The MARS-MD algorithm improves on the CMD
algorithm by adding appropriate constraints to specific combinations of materials.
Three classes of voxels are identified using SST - air, soft tissue, and dense material. Air
voxels are treated as empty by the MARS-MD algorithm. Soft tissue voxels are approximated
as a combination of lipid and water and are assumed to satisfy volume conservation (since
lipid can only dissolve in water through emulsion). Dense material voxels are considered to
contain either a dense solid material (i.e. bone or metal) or contrast pharmaceutical in
solution (i.e. iodine contrast in blood). Since lipid and water have similar attenuation
properties they are approximated to contribute to the same material signal (water) if the
voxel is classified as containing dense material.
The MARS-MD algorithm defined below can be summarised by the following steps: The SST
algorithm is used to determine if a voxel contains soft tissue or dense material. If a voxel is
identified as soft tissue then the voxel is decomposed into lipid and water using volume
constrained non-negative linear least squares. If the voxel is identified as dense material
then it is decomposed using the CMD algorithm. The material combinations checked in the
CMD calculation include each dense material individually and each dense material paired
with water. The acceptable solution range for each material in CMD is left unset (i.e. will
allow solutions from 0 → ∞) in the version of MARS-MD as disclosed herein, although this is
not intended to be limiting.
Algorithm 3.0 MARS-MD algorithm
The MARS-MD algorithm 800 as a computer implemented method is summarised in Figure
In the method described in Figure 19, image data from a multi-energy CT scan is received by
a processor. It is envisaged that multi-energy CT image data may be generated from a
scanning system directly linked to the processing system, or received from a remote
location via a network. Image data is received by processor 810 then if non-reconstructed, is
reconstructed 820 using known data reconstruction techniques, for example an algebraic
reconstruction technique, to produce a set of reconstructed voxels.
Reconstructed voxel data is then compared to a reference set of material signal amplitude
and noise properties 830 stored in a database and the voxels then classified 840 into air 850,
low density 870 or high density 880 voxels based on comparison with the reference set.
If the voxel is classified as air then the voxel is given a solution of zero attenuation and are
exempt from further analysis. Voxels classified as low density 870 undergo application of
volume constrained non-negative least squares calculation to aid in material identification.
Volume constrained means that the volume fraction of lipid plus the volume fraction of
water is at most 1. The volume is constrained to “at most 1” as there may be some air in the
volume, such as in the lungs or in a voxel at an air-tissue boundary.
Voxels classified as high density 860 undergo further processing steps associated with the
CMD algorithm as discussed above.
Based on the results of the in steps 810 through to 871, identification of one or more
specific materials is established and the information communicated to a user interface.
As with above, examples of such user interfaces include graphical user interfaces or visual
user interfaces including one or more monotone (grey scale or single colour) images, where
the intensity is proportional to quantity in a voxel; and multi-colour images with different
colours representing different materials.
We can further compare the performance of the MARS-MD algorithm to the CMD
algorithm. The first comparison shows that the MARS-MD algorithm improves on the six
material decomposition of the multi-contrast phantom dataset presented for the CMD
algorithm. A second comparison of these algorithms using a dataset named FatCaFe is
presented to demonstrate the benefit that the segmentation component of MARS-MD has
for reducing incorrect allocation of soft tissue materials as dense materials.
To show the general performance of the MARS-MD algorithm compared to the CMD
algorithm it has been applied to the multi-contrast phantom dataset presented above for
CMD (see Figure 12 ) using identical image and material basis inputs. The covariance matrix
for the MARS-MD algorithm was estimated from a large homogeneous region of air voxels.
The results of the material decomposition algorithm using the MARS-MD algorithm is
shown in Figure 18, and a further representation of this is given in Figure 22, where 170
shows the soft tissue MD and 171 shows the dense material MD..
The differences between the MARS-MD and CMD algorithms are in the segmentation to
separate dense and soft tissue voxels, and the addition of a volume fraction conservation
constraint on the lipid-water combination. Therefore any voxels identified as dense material
will decompose exactly the same as they did in CMD; and soft tissue voxels are expected to
have physically plausible solutions (unlike the 1.5 g/ml lipid solution from the CMD
algorithm).
The lowest concentrations of gold and gadolinium in this decomposition example have been
identified as water. This result is due to the SST segmentation identifying those
concentrations to be indistinguishable from water in regards to the level of noise in the
data. However, another consequence of the segmentation is that there is significantly less
misidentification of dense materials in the water capillary and PMMA region.
There is significant improvement in the allocation of lipid and water in this decomposition
compared to the CMD decomposition. The lipid image only identifies PCA tube plastic and
edge blurring artefacts from the median filter. The water image shows water in every
capillary. The lipid-water decomposition is also observed to be more robust due to the
homogeneous allocation of water to PMMA.
The median concentrations of each dense material region in the decomposition (from the
material decomposition) were compared to the known concentrations of each solution as
seen in Figure 23, excluding the two concentrations which were identified as soft tissue. This
result shows reasonable accuracy of the MARS-MD algorithm for this dataset. It should also
be noted that this result will be the same for the CMD algorithm.
FatCaFe Phantom
FatCaFe is a known phantom dataset consisting of a solid PMMA cylinder with 6 capillaries
filled with the materials: 2.0 mol/L CaCl2 solution, 0.4 mol/L Fe(NO3)3 solution, 0.01 mol/L
iodine solution, sunflower oil, water, and air. Data was collected using a Medipix-3 (Si) quad
detector; a 50 kVp tungsten x-ray beam; and measured using six energy bands (9.8−50,
.1−50, 20.4−50, 25.6−50, 30.9−50 and 36.2−50 keV).
Material decomposition of this dataset using CMD 190 and MARS-MD 191 algorithms are
presented in Figure 24 together with reconstructed image 194 which shows the differences
in material identification using the different decomposition methods. The benefit of the
segmentation step in the MARS-MD algorithm can be observed from the misidentification of
PMMA as iodine in the CMD decomposition at position 192, when compared to the MARS-
MD decomposition, where PMMA is correctly identified at position 193 as shown by the
shaded circle which was absent at 192.
In one preferred embodiment of the invention, the MARS-MD algorithm disclosed is
implemented using MATLAB program developed for post-spatial-reconstruction material
decomposition of multi-energy CT datasets. The material decomposition used in this
program is a version of the CMD algorithm that has been modified to separate the dense
material and soft tissue problems and to apply the volume fraction conservation constraint
to the soft tissue problem.
The separation of the soft tissue and dense material problems aid material decomposition
by preventing noise in the soft tissue voxels being incorrectly decomposed into dense
materials. As a consequence of this improvement, any low concentrations of dense
materials whose signal is very close to or in the noise level will be selectively represented as
soft tissue instead of dense material. However, this is not an issue if this cut-off
concentration is close to the detection limit for the multi-energy CT scanner acquiring the
data.
The mass attenuation coefficients for lipid and water are virtually identical for x-rays above
50 keV, where these x-rays contribute the majority of the signal measured in the human
imaging range. Since lipid and water are immiscible, the relationship between conservation
of volume fractions and linear attenuation intensity of soft tissues can hold more useful
information than the multi-energy measurement by itself. This is illustrated in the addition
of volume conservation to the soft tissue decomposition in the MARS-MD algorithm
producing a more sensible result than the CMD algorithm.
It has been shown that the MARS-MD algorithm can easily achieve a reasonable six material
decomposition using 4 energy bands in the human imaging range.
The computer implemented methods of the present invention may be operated using the
systems as exemplified in Figures 20 and 21.
In use the system 300 of Figure 20 includes a multi-energy CT imaging system 301. Multi-
energy CT images are taken of an object/sample or patient of interest and the image data
set delivered via communications network 302 to computer system 303. Computer system
303 includes processor 304, data storage medium 305 and server 306.
Processor 304 receives the image data set from communications network 302 and
implements the processing steps of the methods of the present invention together with
data storage medium 305. Server 306 serves data from computer system 303 to interface
307.
Interface 307 may be an application program interface (API), a user interface, software or
hardware interface.
Figure 21 shows an alternate system 600 of the present invention, where multi-energy CT
image data is received over a communications network 602 by a processor 604 within
computer system 603. Multi-energy CT data is received over communications network 602
from an external source via known communications protocols for example, email, internet,
FTP or HTML.
As with system 300 computer system 603 includes processor 604, data storage medium 605
and server 606. Processor 604 receives the image data set from communications network
602 and implements the processing steps of the methods of the present invention together
with data storage medium 605. Server 606 serves data from computer system 603 to
interface 607.
Interface 607 may be an application program interface (API), a user interface, software or
hardware interface for example.
The various operations of methods described above may be performed by any suitable
means capable of performing the operations, such as various hardware and/or software
component(s), circuits, and/or module(s). Generally, any operations illustrated in the
Figures may be performed by corresponding functional means capable of performing the
same or equivalent operations.
The various illustrative modules and algorithm steps described in connection with the
embodiments disclosed herein may be implemented as electronic hardware, computer
software, or combinations of both. To clearly illustrate this interchangeability of hardware
and software, various illustrative components, modules, and steps have been described
above generally in terms of their functionality. Whether such functionality is implemented as
hardware or software depends upon the particular application and design constraints
imposed on the overall system. The described functionality may be implemented in varying
ways for each particular application, but such implementation decisions should not be
interpreted as causing a departure from the scope of the embodiments of the invention.
The steps of a method or algorithm and functions described in connection with the
embodiments disclosed herein may be embodied directly in hardware, in a software module
executed by a processor, or in a combination of the two. If implemented in software, the
functions may be stored on or transmitted over as one or more instructions or code on a
tangible, non-transitory computer-readable medium.
A software module may reside in Random Access Memory (RAM), flash memory, Read Only
Memory (ROM), Electrically Programmable ROM (EPROM), Electrically Erasable
Programmable ROM (EEPROM), registers, hard disk, a removable disk, a CD ROM, or any
other form of storage medium known in the art.
A storage medium is coupled to the processor such that the processor can read information
from, and write information to, the storage medium. In the alternative, the storage medium
may be integral to the processor. Disk and disc, as used herein, includes compact disc (CD),
laser disc, optical disc, digital versatile disc (DVD), floppy disk and blu ray disc where disks
usually reproduce data magnetically, while discs reproduce data optically with lasers.
Combinations of the above should also be included within the scope of computer readable
media. The processor and the storage medium may reside in an ASIC. The ASIC may reside
in a user terminal. In the alternative, the processor and the storage medium may reside as
discrete components in a user terminal.
The success of the MARS-MD algorithm can be contributed to the following three aspects: it
searches for sparse solutions; the combinatorial nature of the algorithm which allows simple
application of constraints to specific material combinations; and it prevents dense materials
being allocated to low attenuating regions by segmenting the problem into two
independent problems.
The MARS-MD algorithm in combination with multi-energy x-ray scanning as discussed
above has a wide range of applications, both medical and otherwise. As would be
appreciated by a person skilled in the art, the algorithms associated with MARS-MD may be
added, modified or used in a single-step analysis with spatial reconstruction techniques in
order to perform effectively for particular applications. Those skilled in the art will recognise
that iterative methods of performing spatial reconstruction can be interwoven with the
algorithms and methods described here, and such iterative methods will give rise to more
rapid, and better material quantification, as the beam hardening artefacts that arise from
the width of the energy ranges will be handled by such methods. However, the core
methods performed by the algorithm will essentially remain unchanged. Some of those
applications are discussed in further detail below in general terms which are non-intended
to be limiting.
Unless otherwise stated, the use of the MARS-MD algorithm in conjunction with multi-
energy x-ray technology, either alone or in conjunction with other methods, for material
identification and quantification is assumed in each application. It should also be assumed
that all methods relating to human or animal diagnosis or monitoring include both alive and
deceased subjects, or tissue samples therefrom.
Where the below applications utilise the methods of the present invention or parts thereof,
they are intended for use as computer implemented methods, utilising the systems and
apparatus described above, or parts thereof.
Atherosclerosis Imaging
Atherosclerosis is an inflammatory disease which results in narrowing and hardening of the
vascular system through the formation of atherosclerotic plaques, or atheromas in the
arterial wall. These plaques are characterised by a lipid build up (lipid core) and calcifications
(in older plaques). If an atherosclerotic plaque is unstable then it has the possibility of
rupturing, causing heart attack, stroke or infarction and potentially death.
The methods described herein may be applied to multi-energy x-ray data to spatially locate
and quantify components of atheroma plaque that indicate the plaque is unstable or
vulnerable. The method may also be used to monitor the plaque serially over time with or
without treatment to determine whether the plaque is becoming more or less vulnerable.
The use of the current methods in atheroma imaging allows in vivo “histology” of atheroma,
and drug discovery for stabilising vulnerable atheroma plaque. Vulnerable or unstable in this
context means a piece of plaque is likely to break off from the vessel wall and block a critical
vessel downstream causing complications such as heart attack or stroke or infarction unless
it is stabilized. The site of atheroma may be anywhere in the body – the carotid and
coronary arteries are the sites for atheroma causing stroke and heart attack.
The specific components of vulnerable plaque that may be identified and quantified using
multi-energy x-ray imaging include inflammatory cells such as monocytes and macrophages;
lipid core; fibrous cap; haemorrhage (bleeding) within plaque and/or new vessels within
plaque. This list is not intended to be limiting and other cell, tissue or material may also be
quantified and identified.
The different components may be targeted with a nanocontrast agent comprising a
nanoparticle of any shape, for example nanorods, based on metals such as gold, gadolinium,
iodine, hafnium, tantalum, bismuth, ytterbium, platinum, yttrium, rubidium for example,
that are coated with a material to make them safe to administer. Often a biologically active
component such as a ligand or antibody or part of an antibody that will specifically bind to a
specific cell surface marker, or be incorporated into a specific cell or tissue, with or without
an accompanying pharmaceutical attached will also be incorporated. The nanocontrast
agent may be delivered by injection, topical application, or incorporated within an
implantable device or scaffold such as a metal or biological stent or other drug delivery
system.
The quantification of the material (e.g. lipid, macrophages, fibrous tissue) is based on either
measuring the tissue directly, or measuring the nanoparticle contrast marker tagged to that
tissue. For nanocontrast agents, the quantification involves a calibration step where
different but known concentrations of the metal (gold, gadolinium, iodine etc.) are imaged,
Hounsfield units (HU) plotted against energy, and a calibration curve expressed as HU on x-
axis, and concentration expressed in mg/ml or µg/µL is generated.
The energy related HU spectrum of the specific nanocontrast agent in the plaque is
determined, and the concentration or amount of the nanocontrast at each spatial location is
determined from the calibration curve.
The inventors have found that using the methods of the current invention, five or more
different target components of the plaque, including drug delivery, can be measured from a
single 3D volume scan. The quantification of drug delivery to the atheroma site can be
obtained in the same way by combining the drug or pharmaceutical to the nanocontrast
agent or separately labelling the drug with a metal marker (gold, gadolinium, iodine etc.).
The method may be applied to excised tissue samples, euthanized animals, live animals or
humans. By repeating imaging at different time points in small animal models (mice, rats,
rabbits etc.) or large animal models (pigs, sheep, deer, primates), or in humans, the
inflammatory response can be monitored, allowing opportunities to modify treatments
based on knowledge of the inflammatory process occurring in situ at each time point.
In use, multi-energy CT using MARS-MD material decomposition has been used for
identifying
signs of instability in atherosclerotic plaque. Material decompositions from two different
studies are discussed below: identifying intrinsic plaque structure (without contrast) for
categorising instability; and using targeted gold nano-particles to identify unstable
thrombotic regions of plaque. All imaging has been done on excised atherosclerotic plaque.
The purpose of locating thrombotic regions inside a plaque is that they typically occur in
unstable plaque, and therefore the number of thrombi can be used as a measure of plaque
vulnerability.
Material decomposition in this work was used to distinguish regions of concentrated gold
(at sites of thrombosis) from the calcifications which occur inside plaques.
Shaded material decomposition images of a plaque from this study are shown in Figure 25,
where image 200 shows a region where gold is attached to thrombosis in the plaque,
whereas the image 201 shows a large calcification inside the plaque. Reconstructed
Hounsfield unit images 202 and 203 are provided on the left hand side which show that the
gold nano-particles at the thrombosis site and the calcification are indistinguishable in a
standard CT scan. The data used for this material decomposition was collected using a CdTe-
Medipix-2 (CdTe) MXR detector; 120 kVp tungsten x-ray beam; and measured using four
energy bands (10 − 120, 25 − 120, 55 − 120 and 83 − 120 keV).
Studies using multi-energy CT to image atherosclerotic plaques without contrast
pharmaceuticals were performed to identify the intrinsic structure of plaques (i.e.
distribution of lipid core and calcifications) using multi-energy CT and find what correlations
exist between the structure measurable by a multi-energy CT scanner and plaque
vulnerability.
A 3D material decomposition image generated using the material decomposition methods
of the present invention of a plaque from a carotid artery is shown in Figure 26. The
different materials are indicated by different shaded areas, water 210, lipid 211 and calcium
212. The lipid core 213 in the plaque is visible in the decomposition image and can be
matched to the lipid core 214 seen in the photo taken of the plaque prior to scanning.
Calcifications 215 are shown in both the decomposed and reconstructed images that many
calcifications are present in the plaque.
Bone densitometry and bone health
Bone physiology is a dynamic process. Abnormalities of bone turnover are reflected in bone
densitometry of the part of the bone nearest or involved in the disease process. For
instance, the part of the bone near an inflamed joint becomes porotic (reduced density),
cancer in bone can either increase or decrease the bone density and change the bone
architecture and fracture risk increases in women with post-menopausal osteoporosis.
The methods of the present invention may be used to determine bone densitometry for any
part of any bone by measuring the regional calcium hydroxyapatite concentration in situ.
This is achieved by measuring the energy dependent Hounsfield units in the volume of bone
of interest, reading the corresponding hydroxyapatite concentration from a calibration
curve derived from measuring energy dependent Hounsfield units in a reference set of
known concentrations of hydroxyapatite.
Using the methods of the present invention, bone densitometry can be measured at the
same time as other features of bone health such as trabecular thickness, orientation and
spacing, as well as cartilage health of the bone close to a joint; or assessment of cancer
within bone; or infection or inflammation of bone or adjacent cartilage.
Exemplary imaging of osteoarthritic cartilage has also been undertaken using the methods
of the present invention. In one example of this application excised cartilage samples were
scanned in combination with an iodine contrast (Hexabrix) which has the property that it is
drawn into osteoarthritic tissue. The purpose of this investigation was to develop a non-
invasive method for diagnosing severity of osteoporosis arthritis.
The data used in the following material decomposition can be seen in Figures 27 and 28. The
scan is of an excised arthritic human tibial plateau which has been incubated in an iodine
contrast (Hexabrix) solution. The data was collected using a CdTe-Medipix-3RX (CdTe)
detector; 80 kVp tungsten x-ray beam; and measured using four energy bands (20 − 80, 28 −
80, 30 − 80, and 40 − 80 keV).
In the material decomposition images in Figure 27 it can be seen when comparing the water
image 220 and iodine image 221 that the iodine contrast has penetrated into the cartilage.
The 3D material decomposition image in Figure 28 shows a region where iodine contrast
230 penetrates the cartilage effectively reaching the bone underneath, thereby showing a
region of severe arthritis.
Joint and cartilage imaging
The methods of the present invention can be used to extract molecular information relating
to an ionic contrast agent and bone from an anatomical joint. The extracted signal will be of
the material type and density that can be used to classify disease processes such as
osteoarthritis (OA). The method provides molecular and functional information at high spatial
resolution suitable for imaging of thin cartilage layers found in articulating surfaces of synovial
joints such as the knee, hip, shoulder, and small joints of the extremities.
In one possible example of use, the imaging method involves injecting an ionic contrast agent
to the joint space and acquiring multi-energy images of the cartilage-subchondral interface.
Ionic contrast agents of concentrations starting from 10 mg/cc can be used to achieve
equilibrium partitioning between glycosaminoglycans (present in the extracellular matrix of
the cartilage) and the ionic agent.
Anionic and cationic contrast agents can be used for the multi-energy imaging. Examples of
currently approved anionic contrast agents include Hexabrix (iodine based) and Multihance
(gadolinium based) for imaging, but the methodology may apply to any current or future
anionic or cationic contrast agent containing an element which is identifiable and quantifiable
on spectral imaging using the methods of the present invention.
Negatively charged GAG repels anionic contrast agents and attracts cationic contrast agents.
With osteoarthritis exhibiting non-linear depletion of GAG along the cartilage depth, density
quantification of contrast agents using the current methods provides a system to grade
cartilage health. Reference concentrations of the contrast agent employed and
hydroxyapatite are used as an input to the MARS-MD algorithm to segment and quantify the
contrast agent and subchondral bone density. A volume preservation constraint can then be
employed to classify single and/or a combination of materials within a volume element.
The MARS-MD algorithm with or without nanocontrast can be applied to the multi-energy x-
ray data to measure collagen content in cartilage, fibrous tissue or bone.
One end result of the joint and cartilage imaging method described above is a grading system
to determine cartilage health and onset of cartilage degeneration enabling early diagnosis of
osteoarthritis. Each material volume extracted using the MARS-MD algorithm represents a
tissue-type or contrast agent or combination of both, with density information as an
additional dimension besides the existing spatial dimensions. The MARS-MD algorithm
provides localisation (contrast density vs. cartilage depth) and quantification (contrast density
vs. cartilage health) and is directly related to the disease process.
Subchondral bone density is influenced by osteoarthritis and osteoporosis, and can be
measured using MARS-MD method of the present invention. The MARS-MD algorithm
enables measurement and monitoring of cartilage health including evaluation of the
effectiveness of current and future cartilage repair treatment strategies in any joint disease
affecting cartilage health, principally primary or secondary osteoarthritis. By repeating
imaging at different time points in small animal models (mice, rats, rabbits etc.) or large
animal models (pigs, sheep, deer, primates), or in humans, the disease process can be
monitored, allowing opportunities to modify treatments based on knowledge of the
inflammatory process occurring in situ at each time point.
Cancer
The MARS-MD method can be applied to cancer imaging to detect, localize, and quantify
biomarkers of specific cancers in situ, determine heterogeneity of tumour cell markers and
how tumour marker expression changes over time, in order to personalise cancer treatment
so it matches the biology of the cancer.
Quantifiable nanocontrast agents can be used to label specific tumour cell markers, and
markers of the cellular immune response (macrophages, T cells, and other immune
response cell types) at any tumour site. The application can be for any tumour or cancer in a
human or animal (including but not limited to carcinoma, neural, endocrine,
lymphoma/leukaemia, germ cell, sarcoma, blastoma) in any organ in the head, neck, chest,
abdomen and limbs (including but not limited to gastrointestinal tract, urinary tract,
respiratory tract, skin, blood, brain and nervous system, endocrine glands) at any age
(foetus, neonate, infant, child, adult).
The nanocontrast agents suitable for use with current method for identifying or monitoring
cancer are functionalised nanoparticles. These typically include –a metal core, a coating to
make them safe to administer in the body, and a ligand or aptimer or other biologically
active macromolecule which specifically targets a cell marker. Two or more, usually five or
more, different target components of the cancer including drug delivery can be measured
from a single 3D volume scan.
The quantification of drug delivery to the tumour site can be obtained in the same way by
combining the drug or pharmaceutical with the nanocontrast agent or separately labelling
the drug with a metal marker such as gold, gadolinium or iodine. The method may be
applied to excised tissue samples, euthanized animals, live animals or humans. By repeating
imaging at different time points in small animal models or large animal models, the efficacy
or rate of incorporation or growth of the tissue types can be monitored and modified in the
individual.
In a similar fashion, the MARS-MD method can identify and quantify markers of hypoxia in
tumours, fibrotic components of tumour, and microcalcifications in tumours.
Inflammatory and infectious diseases
Inflammation is a key pathological process in many acute and chronic diseases including but
not limited to infection, arthritides, atherosclerosis, dementia, diabetes, autoimmune
diseases and many cancers. Inflammation may be present at any site in the head, neck,
chest, abdomen, pelvis, limbs and extremities. The methods of the present invention in
combination with the use of nanocontrast agents can be used to identify and quantify the
components of the inflammatory process and immune response, including but not limited
to neutrophils, lymphocytes, natural killer cells, T cells, B cells, innate lymphoid cells,
thymocytes, granulocytes, monocytes, macrophages, fibroblasts, eosinophils, platelets,
megakaryocytes and the precursors of these cells.
In the case of infection, the MARS-MD algorithm can be used to identify and quantify the
pathogen (including but not limited to bacteria, mycobacteria, viruses, protozoa, fungi,
worms and prions) causing infection on the image – a form of microscope without the need
to cut up or remove any tissue from the body. This is especially useful for hard to diagnose
infections, or infections not responding rapidly to treatment. The method involves using a
range of different functionalised metal containing nanocontrast agents targeted to different
potential pathogens and which could be quantified by a single multi-energy CT scan. Each
nanocontrast is specifically targeted to a characteristic marker for the pathogen.
In the case of arthritis caused by crystals such as monosodium urate, calcium-
pyrophosphate dihydrate, calcium hydroxyapatite, and calcium oxalate (diseases such as
gout and pseudogout), the MARS-MD method can identify the type of crystal within the
joint enabling faster and more specific treatment. Simultaneously, that is in the same multi-
energy CT scan, the MARS-MD algorithm can be used to determine the severity of
inflammation, response to treatment and drug delivery.
In the case of altered immune competence, MARS-MD may be used to monitor and
measure the reduction or increase in immune cells at sites of infection or other disease
entities in the immunologically compromised individual.
The different components of the inflammatory/immune response may be targeted with a
nanocontrast agent comprising a nanoparticle of any shape, for example nanorods based on
metals such as gold, gadolinium, iodine, hafnium, tantalum, bismuth, ytterbium, platinum,
yttrium, rubidium etc., coated with a material to make it safe to administer, and often a
biologically active component such as a ligand or antibody or part of an antibody that will
specifically bind to a specific cell surface marker, or be incorporated into a specific cell or
tissue, with or without an accompanying pharmaceutical attached. The nanocontrast agent
may be delivered by injection, topical application, or incorporated within an implantable
device or scaffold such as a metal or biological stent.
Scaffolds and engineered tissues in regenerative medicine
A range of tissues can be engineered then placed in the body to help regeneration of body
tissue or parts. This includes but is not restricted to bone, cartilage, nerve tissue, bladder,
bowel, muscle, blood vessels). More complex structures such as liver or pancreas are
known to be made by additive manufacturing techniques. Many of these engineered tissues
start with a scaffold then cell or tissue types are grown in or on these scaffold before they
are implanted.
Scaffolds may be metal, such as stainless steel, titanium, TiAl V , tantalum, cobalt chrome
for example or organic (such as collagen, fibrin, hydrogel, gelatin, nanofibre, aerogel,
bioglass, hydroxyapatite, chitosan for example) and they may be bioactive. They may be
coated with growth factors or growth stimulators either biological or non-biological such as
strontium, magnesium.
The methods of the present invention can be used to noninvasively determine the growth of
the tissue in/on the scaffold, and to monitor the degree to which the engineered tissue is
incorporating into the body.
The application of the MARS-MD algorithm to multi-energy x-ray data can be used to
identify the scaffold and its components, and quantify the new tissue forming, and the
resorption of the scaffold itself.
MARS-MD provides this identification and quantification in two ways. Firstly, by directly
identifying the material such as the metal within a scaffold, or by identifying an agent
eluting from a scaffold. Secondly, by targeting specific cell or tissue types with nanocontrast
agents comprising a nanoparticle of any shape based on metals such as gold, gadolinium,
iodine, hafnium, tantalum, bismuth, ytterbium, platinum, yttrium, rubidium etc., coated
with a material to make it safe to administer, and often a biologically active component such
as a ligand or antibody or part of an antibody that will specifically bind to a specific cell
surface marker, or be incorporated into a specific cell or tissue, with or without an
accompanying pharmaceutical attached.
The nanocontrast agent may be delivered by injection, topical application, or incorporated
within the implantable scaffold or stent.
The quantification of the material is based on either measuring the tissue directly, or
measuring the nanoparticle contrast marker tagged to that tissue.
The method may be applied to excised tissue samples, euthanized animals, live animals or
humans. By repeating imaging at different time points in small animal models (mice, rats,
rabbits etc.) or large animal models (pigs, sheep, deer, primates), or in humans, the region
of interest can be monitored, allowing opportunities to modify treatment.
For orthopaedic and/or dental applications, the methods of the present invention can be
used to determine the ingrowth of bone into an implant be measuring the bone quantity or
density at the bone/implant interface. Many orthopaedic and dental implants in use today
are formed with porous coatings or apertures within the implant surface to encourage
osseointegration of healthy bone with the implant surface, stabilising the implant within the
body. On insertion of an implant no bone ingrowth will be present at the bone/implant
interface. By measuring the bone density and position over time using multi-energy CT with
the MARS-MD techniques described herein, the progress of the bone integrating with the
implant can be measured and used to help determine the success and progress of the
implantation.
Similar measurements can also be used to determine implant failure or degeneration. By
using the scanning methods and algorithms described herein, implants showing little or no
connection between implant and bone at what should be the bone/implant interface can
identify a failed or failing implant that will need revising. By conducting such measurements
over a time period, the success or failure of implants can be monitored and patient
treatment programmes can be managed more effectively to ensure positive outcomes.
Lipid Deposition
Intracellular lipid in the liver is a feature of the fatty liver disease-cirrhosis-hepatocellular
carcinoma sequence. Quantification of fat within the liver, globally and regionally is useful in
determining when, and how to prevent this sequence progressing. Multi-energy CT used
with the MARS-MD algorithm may be used to quantify the lipid/fat directly by distinguishing
it from water-like cells, and fibrous tissue.
Intra-tumoral fat is a feature of some benign and malignant tumours. Identifying it is very
helpful in diagnosis of such tumours.
Multi-energy CT with the MARS-MD algorithm may be used to identify and quantify fat,
whether intracellular or extracellular in any body organ or tissue anywhere in the head,
neck, chest, abdomen, pelvis or limbs. In one example of the use in lipid quantification, as
lipid is an integral part of myelinated nerve tissue in the brain and spinal cord, brain diseases
which alter the amount of myelin, or which lead to displacement or destruction can be
assessed.
Quantification of fat in tissue may also be used outside the medical field. Fat content in
meat, particularly when mixed through the texture (for example marbling in steaks) is of
prime interest to the entire “farm to plate” meat industry. Using techniques outlines above,
the methods described herein may be used to measure and grade fat content and
distribution within meat at any stage in the processing chain from live animal to carcass to
final meat cut. The methods may be applied to any animal whether farmed or in the wild,
including but not confined to sheep and lamb, pigs, cattle, deer, fish, and shellfish.
Measuring permeability and pore size
As the liver becomes diseased, the pore size in the liver sieve changes; Multi-energy CT with
the MARS-MD algorithm can be used to measure the permeability of blood vessels, the
pore size of the liver sieve, the integrity of the blood brain barrier, renal etc. by using
different nanomaterials each of a different size to measure the effective pore size.
New blood vessels in tumours tend to be leaky. This allows them to grow. Multi-energy x-ray
scanning and the MARS-MD algorithm can assess neoangiogenesis in tumours and other
diseases by measuring how much non-functionalised nanoparticle contrast persists in the
extracellular space hours after intravascular injection.
In one embodiment the method involves using metal based nanoparticles coated so they
can be transported through the blood stream safely. They can be attached to
macromolecule drugs for site specific delivery. Each different nanoparticle is of a different
size e.g. 15nm, 50nm, 100nm, 200nm.
After injection, the nanoparticles circulate. Those small enough to pass through the
junctions between endothelial cells in the neovasculature will accumulate locally in the
extracellular space. The larger nanoparticles continue to circulate and may be taken up by
the reticuloendothelial system of the liver and spleen. The multi-energy imaging is
performed at 12 – 36 or more preferably 18-24 hours after administration of the
nanoparticles.
Measurement of the nanoparticle content at the site of interest using the MARS-MD
algorithm quantifies the degree of angiogenesis. This can be monitored over time and in
conjunction with treatment. Macromolecular drugs can be delivered to desired locations
with leaky vessels in this way, and the drug delivery quantified.
Material decomposition for breast imaging
Multi-energy CT scanning used with the MARS-MD algorithm can be used for identification
and quantification of benign and malignant breast diseases. This may involve the use of a
number of the applications described in more detail above, and includes imaging of fat in
the breast and microcalcifications including distinguishing calcium oxalate from calcium
hydroxyapatite. Nanocontrast agents targeted to specific breast tumour cell targets
(including but not restricted to HER-2 and oestrogen receptors) with or without provision
for targeted drug delivery may also be used for targeted imaging of breast tumours or
tissues.
Drug delivery
Toxic drugs can be delivered more safely to tumours, infection, and other disease sites if
they are incorporated into larger structures such as macromolecules or micelles or
liposomes. If the macromolecule or liposome also contains a nanoparticle/nanocontrast,
then the MARS-MD algorithm can measure how much drug or pharmaceutical is delivered
to the site of interest. This can be for active drugs within the macromolecule/micelle or pro-
drugs which become activated at the target site. MARS-MD can be used for assessing not
only drug delivery but assessing drug activation if activation involves cleaving the active
component.
The active drug component is labelled with one nanoparticle, and the inactive component
with a different nanoparticle. The MARS-MD algorithm identifies, distinguishes and
measures both components. If both are together in the target area, then that measures
prodrug delivery. If later only the active nanoparticle marker is measured, then the drug has
been activated, and the inactive component metabolised.
Combination scanning with PET or SPECT
Alternative scanning techniques such as PET or SPECT can be used to indicate a range of
components within a body, for example residual sites of cancer after treatment. Multi-
energy CT may be combined with PET or SPECT to further aid in the monitoring and
quantification of such components.
In one example of use which is not intended to be limiting, a nanocontrast labelled drug
may be administered to a patient and multi-energy CT scanning used with the MARS-MD
algorithm used to determine if there is successful drug delivery to the residual tumour.
Simultaneous Contrast Imaging
Mice are a common test subject used in biomedical research for a variety of reasons
including
Size and reproduction speed. They are well understood and have many aspects similar to
humans both physically and in their genetics. One application that mice are used for is
simultaneous multiple contrast imaging. The high energy resolution of multi-energy CT and
the MARS-MD algorithm enables discrimination of many different contrast pharmaceuticals
simultaneously from soft tissue and bone. An advantage of multi-contrast imaging is that it
opens up possibilities for functional imaging using targeted multi-contrast pharmaceuticals.
Mouse 12
“Mouse 12” is a dataset that has been previously published using a PCA material
decomposition
technique (N. Anderson et al. 2010 [25]) to show that both barium and iodine can be
discriminated simultaneously in mice using multi-energy CT. Since this publication, the
dataset has been reprocessed using the methods of the present invention and the results
shown in Figure 29.
This data was collected using a Si-Medipix-2MXR detector; 75 kVp tungsten x-ray beam; and
measured using four energy bands (12−75, 23−75, 30−75, and 33−75 keV). The 3D material
decomposition image shows three materials – bone 240, iodine 241 in the heart, and
barium 242 in the lungs.
The methods of the present invention have a number of distinct advantages over the
current known technology.
The inventors have developed a material decomposition algorithm which can discriminate
between a large number of materials simultaneously. Three algorithms are disclosed: the
statistical segmentation technique, combinatorial material decomposition, and the MARS-
MD algorithm. By using these techniques the inventors have achieved a six-material
decomposition using four energy bands which is a significant advancement over the current
known art.
SST is designed to use multi-energy information to assist segmentation. It is demonstrated
that using multiple energies enables images to be segmented at lower levels of SNR than if
only a single energy is used.
Combinatorial material decomposition (CMD) is a method developed for finding sparse
solutions to the post-spatial-reconstruction material decomposition problem. The solution
for each voxel is calculated using each sub-matrix of the material matrix (with columns up to
maximum number of materials desired in the solution) and the best result is selected. The
combinatorial nature of this approach enables non-physical solutions and material
combinations to simply be rejected.
The inventors have further shown that the CMD algorithm is capable of decomposing dense
materials into six materials. The CMD algorithm was compared to two basic material
decomposition techniques, linear least squares and non-negative linear least squares,
neither of which were are able to achieve the same degree of discrimination shown by the
CMD algorithm.
The MARS-MD algorithm is an enhancement of the CMD algorithm using further constraints.
First the SST algorithm is used to identify voxels either containing soft tissue or dense
material.
Second is that a volume fraction conservation constraint is included in the soft tissue
decomposition. These additional constraints both reduce the misidentification of low
attenuating materials as dense materials and ensures that the solution for lipid and water
physically reasonable.
When used on the same dataset, the MARS-MD algorithm is shown to have far less material
misidentification than the CMD algorithm. The only exception to this is for very low
concentrations of dense materials which are identified as soft tissue due to the level of
noise in
the data.
The entire disclosures of all applications, patents and publications cited above and below, if
any, are herein incorporated by reference.
Reference to any prior art in this specification is not, and should not be taken as, an
acknowledgement or any form of suggestion that that prior art forms part of the common
general knowledge in the field of endeavour in any country in the world.
Where in the foregoing description reference has been made to integers or components
having known equivalents thereof, those integers are herein incorporated as if individually
set forth.
It should be noted that various changes and modifications to the presently preferred
embodiments described herein will be apparent to those skilled in the art. Such changes and
modifications may be made without departing from the spirit and scope of the invention
and without diminishing its attendant advantages. It is therefore intended that such changes
and modifications be included within the present invention.
For purposes of summarizing the disclosure, certain aspects, advantages and novel features
of the inventions have been described herein. It is to be understood that not necessarily all
such advantages may be achieved in accordance with any particular embodiment of the
invention. Thus, the invention may be embodied or carried out in a manner that achieves or
optimizes one advantage or group of advantages as taught herein without necessarily
achieving other advantages as may be taught or suggested herein.
Various modifications of the above described embodiments will be readily apparent, and the
generic principles defined herein may be applied to other embodiments without departing
from the spirit or scope of the invention. Thus, the present invention is not intended to be
limited to the embodiments shown herein but is to be accorded the widest scope consistent
with the principles and novel features disclosed herein.
References
P. Sukovic and N. H. Clinthorne, “Basis material decomposition using triple-energy X-ray
computed tomography,” Conference Record - IEEE Instrumentation and Measurement
Technology Conference, vol. 3, pp. 1615–1618, 1999.
M. Firsching, D. Niederl¨ohner, T. Michel, and G. Anton, “Quantitative material
reconstruction in CT with spectroscopic x-ray pixel detectors - A simulation study,” in IEEE
Nuclear Science Symposium Conference Record, vol. 4, pp. 2257–2259, 2007.
H. Q. Le and S. Molloi, “Least squares parameter estimation methods for material
decomposition with energy discriminating detectors,” Med. Phys., vol. 38, pp. 245–255,
2011.
A. M. Alessio and L. R. MacDonald, “Quantitative material characterization from multi-
energy photon counting CT,” Med. Phys., vol. 40(3), p. 031108, 2013.
H. J. Vinegar and S. L. Wellington, “Tomographic imaging of three-phase flow
experiments,”
Review of Scientific Instruments, vol. 58(1), pp. 96–107, 1987.
X. Liu, L. Yu, A. Primak, and C. McCollough, “Quantitative imaging of element
composition
and mass fraction using dual-energy CT: Three-material decomposition,” Med. Phys., vol. 36,
pp. 1602–1609, 2009.
J. Wang, N. Garg, X. Duan, Y. Liu, S. Leng, L. Yu, E. L. Ritman, B. Kantor, and M. C.
H., “Quantification of iron in the presence of calcium with dual-energy computed
tomography
(DECT) in an ex vivo porcine plaque model,” Phys. Med. Biol., vol. 56, pp. 7305–7316, 2011.
H. Q. Le and S. Molloi, “Segmentation and quantification of materials with energy
discriminating computed tomography: A phantom study,” Med. Phys., vol. 38(1), pp. 228–
237, 2011.
J. P. Ronaldson, R. Zainon, N. Scott, S. P. Gieseg, A. P. Butler, P. Butler, and N. G.
Anderson,
“Toward quantifying the composition of soft tissues by spectral CT with Medipix3,” Med.
Phys., vol. 39, pp. 6847–6857, 2012.
A. Rencher, Methods of Multivariate Analysis. John Wiley & Sons, Inc., 1995.
“Tissue Substitutes in Radiation Dosimetry and Measurement,” International
Commission on Radiological Units and Measurements, ICRU Report Issue 44, 1989.
https://w9.siemens.com/cms/oemproducts/home/x-raytoolbox/spektrum/pages/
default.aspx.
M. Berger, J. Hubbell, S. Seltzer, J. Chang, J. Coursey, R. Sukumar, D. Zucker, and K.
Olsen,
“XCOM: Photon Cross Sections Database.” http://www.nist.gov/pml/data/xcom/index.
cfm.
C. J. Bateman, J. McMahon, A. Malpas, N. de Ruiter, S. Bell, A. P. Butler, P. H. Butler, and
P. F. Renaud, “Segmentation enhances material analysis in multi-energy CT: A simulation
study,” in International Conference Image and Vision Computing New Zealand, pp. 190–195,
2013.
E. J. Candes and M. B.Wakin, “An introduction to compressive sampling: A
sensing/sampling paradigm that goes against the common knowledge in data acquisition,”
IEEE Signal Processing Magazine, vol. 25, no. 2, pp. 21–30, 2008.
R. Tibshirani, “Regression Shrinkage and Selection via the LASSO,” Journal of the Royal
Statistical Society B, vol. 58, no. 1, pp. 267–288, 1996.
S. Chen, D. Donoho, and M. Saunders, “Atomic Decomposition by Basis Pursuit,” SIAM
Review, vol. 43, no. 1, pp. 129–159, 2001.
N. D. Tang, N. De Ruiter, J. L. Mohr, A. P. H. Butler, P. H. Butler, and R. Aamir, “Using
algebraic reconstruction in computed tomography,” in ACM International Conference
Proceeding Series, pp. 216–221, 2012.
R. B. Zainon, Spectral Micro-CT Imaging of Ex Vivo Atherosclerotic Plaque. PhD thesis,
University of Canterbury, New Zealand, 2012.
R. Zainon, P. Ronaldson, A. Butler, and P. Butler, “Establishing a linear basis for
quantifying
material composition using spectral CT,” in In Proceedings of 2011 International Conference
on Biomedical Engineering and Biotechnology (BEB2011), IEEE, 2011.
M. F. Walsh, S. J. Nik, S. Procz, M. Pichotka, S. T. Bell, C. J. Bateman, R. M. N. Doesburg,
N. De Ruiter, A. I. Chernoglazov, R. K. Panta, A. P. H. Butler, and P. H. Butler, “Spectral
CT data acquisition with Medipix3.1,” Journal of Instrumentation, vol. 8, no. 10, 2013.
N. G. Anderson and A. P. Butler, “Clinical applications of spectral molecular imaging:
Potential and challenges,” Contrast Media and Molecular Imaging, vol. 9, no. 1, pp. 3–12,
2014.
R. Aamir, Using MARS Spectral CT for Identifying Biomedical Nanoparticles. PhD thesis,
University of Canterbury, 2013.
R. Aamir, A. Chernoglazov, C. J. Bateman, A. P. H. Butler, P. H. Butler, N. G. Anderson,
S. T. Bell, R. K. Panta, J. L. Healy, J. L. Mohr, K. Rajendran, M. F.Walsh, N. De Ruiter, S. P.
Gieseg, T. Woodfield, P. F. Renaud, L. Brooke, S. Abdul-Majid, M. Clyne, R. Glendenning,
P. J. Bones, M. Billinghurst, C. Bartneck, H. Mandalika, R. Grasset, N. Schleich, N. Scott,
S. J. Nik, A. Opie, T. Janmale, D. N. Tang, D. Kim, R. M. Doesburg, R. Zainon, J. P.
Ronaldson, N. J. Cook, D. J. Smithies, and K. Hodge, “MARS spectral molecular imaging of
lamb tissue: Data collection and image analysis,” Journal of Instrumentation, vol. 9, no. 2,
2014.
N. G. Anderson, A. P. Butler, N. J. A. Scott, N. J. Cook, J. S. Butzer, N. Schleich, M.
Firsching,
R. Grasset, N. de Ruiter, M. Campbell, and P. H. Butler, “Spectroscopic (multi-energy) colour
CT distinguishes iodine and barium contrast in mice,” Eur. Radiol., vol. 20, pp. 2126–2134.
Claims (11)
1. A computer-implemented method for selecting a material decomposition algorithm using image data generated using a multi-energy computer tomography (CT) imaging system using three or more energy bands using a computer program product, the method including; a) receiving a reconstructed or non-reconstructed multi-energy CT image data set produced using three or more energy bands in relation to an object; b) storing said data set on a data storage medium; c) if data received in a) is non-reconstructed, processing the data using one or more reconstruction techniques to produce a data set of reconstructed voxels; d) comparing each voxel in the reconstructed data set to a reference set of material signal amplitude and noise properties stored on a data storage medium; e) classifying the voxels into air, low density or high density voxels; f) based on the determination of e) selecting a first material decomposition method to be applied to low density voxels and/or selecting a second material decomposition method to be applied to higher density voxels; and g) presenting the selected first and/or second decomposition method to an interface.
2. The method of claim 1, wherein the method further includes the step of scanning an object using a multi-energy CT system using three or more energy bands to produce an image data set and the step of sending image data to be received at step a).
3. The method of claim 1 or claim 2, wherein the step of classifying voxels as air, low density or high density voxels includes comparing individual voxels to a reference distribution of a specific reference material using the Mahalanobis distance metric and Euclidian distance metric.
4. The method of any one of claims 1 – 3, wherein the step of classifying voxels further includes the step of filtering the data to remove noise.
5. The method of any one of claims 1 – 4, wherein the first material decomposition method at step f) includes using volume constrained non-negative linear least squares to aid material identification.
6. The computer implemented method of any one of claims 1 -4, wherein the second material decomposition method applied at step f) includes the further steps of: - defining excluded material combinations in the data set pre-determined to be disallowed; - calculating, for each of a plurality of reconstructed voxels contained within the data set, a sparse solution for a maximum number of material combinations using a least squares (I2 norm) minimisation subject to a 0-norm constraint inequality for enforcing a maximum number of materials per voxel by combinatorial search over the not excluded material combinations during the least squares minimisation using a processor; - applying rejection criteria to the sparse solutions of c) while performing the combinatorial search to identify one or more materials, wherein the step of applying rejection criteria to the sparse solutions includes the step of setting acceptable solution ranges for each material, and rejecting any sub-problem with a solution outside these ranges.
7. A system for selecting and presenting a material decomposition algorithm using image data generated using a multi-energy computer tomography (CT) imaging system using three or more energy bands, the system comprising: a) a receiver for receiving a reconstructed or non-reconstructed multi-energy CT image data set produced using three or more energy bands in relation to an object; b) a data storage medium for storing said data; c) a processor for processing the data using one or more reconstruction techniques to produce a data set of reconstructed voxels; d) a processor for comparing each voxel in the reconstructed data set to a reference set of material signal amplitude and noise properties stored on a data storage medium; e) a processor for classifying the voxels into air, low density or high density voxels; f) a processor for selecting a first material decomposition method to be applied to low density voxels and/or selecting a second material decomposition method to be applied to higher density voxels; and g) an interface for presenting the selected first and/or second decomposition method to a user.
8. The system of claim 7, wherein the system includes a multi-energy CT scanning system using three of more energy bands for scanning an object using a multi- to produce an image data set and a transmitter for sending image data to a receiver.
9. A computer-implemented method for selecting a material decomposition algorithm using image data generated using a multi-energy computer tomography (CT) imaging system using three or more energy bands, using a computer program product, the method including; a) scanning an object using a multi-energy CT system using three or more energy bands to produce an image data set; b) storing said data set on a data storage medium; c) processing the data using one or more reconstruction techniques to produce a data set of reconstructed voxels; d) comparing each voxel in the reconstructed data set to a reference set of material signal amplitude and noise properties stored on a data storage medium; e) classifying the voxels into air, low density or high density voxels; f) based on the determination of e) selecting a first material decomposition method to be applied to low density voxels and/or selecting a second material decomposition method to be applied to higher density voxels; and g) presenting the selected first and/or second decomposition method to an interface.
10. The method of claim 7, wherein the image data is medical data and the low density voxels represent soft tissue.
11. The method of claim 7, wherein the image data is medical data and the high density voxels represent bone, implants, metals and/or contrasting agents.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ70717615 | 2015-04-20 | ||
NZ707176 | 2015-04-20 | ||
NZ750484A NZ750484B2 (en) | 2015-04-20 | 2016-04-20 | Improving Material Identification using Multi-Energy CT Image Data |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ762916A true NZ762916A (en) | 2021-11-26 |
NZ762916B2 NZ762916B2 (en) | 2022-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021258099B2 (en) | Improving Material Identification using Multi-Energy CT Image Data | |
Palacio‐Mancheno et al. | 3D assessment of cortical bone porosity and tissue mineral density using high‐resolution µCT: effects of resolution and threshold method | |
JP7161212B2 (en) | Data processing device and data processing method in X-ray inspection, and X-ray inspection device equipped with the device | |
Alshipli et al. | Effect of slice thickness on image noise and diagnostic content of single-source-dual energy computed tomography | |
JP6758817B2 (en) | Medical image diagnostic equipment and medical image processing equipment | |
Joshi et al. | Effective atomic number accuracy for kidney stone characterization using spectral CT | |
Zbijewski et al. | Dual‐energy cone‐beam CT with a flat‐panel detector: Effect of reconstruction algorithm on material classification | |
Kawata et al. | Quantitative classification based on CT histogram analysis of non‐small cell lung cancer: Correlation with histopathological characteristics and recurrence‐free survival | |
JP2020535924A (en) | Annotation of image features in diagnostic imaging | |
Ilyas et al. | Dual-energy Computed Tomography: A Reliable and Established Tool for: In vivo: Differentiation of Uric Acid from Nonuric Acid Renal Stones | |
Khan et al. | Application of image processing in detection of bone diseases using x-rays | |
Marar et al. | Mandible bone osteoporosis detection using cone-beam computed tomography | |
Harrar et al. | Quantification of trabecular bone porosity on X-ray images | |
CN107680078B (en) | Image processing method and device | |
Johnson et al. | Breast density quantification with cone-beam CT: a post-mortem study | |
Park et al. | Diagnostic performance for detecting bone marrow edema of the hip on dual-energy CT: Deep learning model vs. musculoskeletal physicians and radiologists | |
Bateman et al. | Segmentation enhances material analysis in multi-energy CT: A simulation study | |
NZ762916A (en) | Improving material identification using multi-energy ct image data | |
NZ762916B2 (en) | Improving Material Identification using Multi-Energy CT Image Data | |
NZ750484B2 (en) | Improving Material Identification using Multi-Energy CT Image Data | |
Hindelang et al. | Bone density determination of moose skeletal remains from Isle Royale National Park using digital image enhancement and quantitative computed tomography (QCT) | |
Ansorena Lujambio | Robustness evaluation of Bone Mineral Density measurements in spectral CT using Three Material Decomposition | |
Pravin et al. | Computer aided diagnosis of osteoporosis using 1st order texture parameters | |
da Silva Carvalho et al. | Characterization of hydroxyapatite tablet by X-ray computed microtomography aiming at the construction of a low-cost bone tissue phantom | |
Jhora et al. | Analysis of Image Fusion Effect in Image Quality of Kidney Stone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2023 BY ANCA LIANA TONCEAN Effective date: 20220315 |
|
LAPS | Patent lapsed |